ifosfamide has been researched along with Neoplasms in 276 studies
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the electronic anti-nausea instrument (EANI) combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy." | 9.19 | Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. ( Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014) |
| " Measurements included carnitine plasma levels and self-reported fatigue using established child or adolescent fatigue scales and were collected during the 2nd cycle of chemotherapy, and repeated on alternating cycles up to cycle 8." | 7.81 | Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents. ( Hockenberry, MJ; Hooke, MC; McCarthy, K; Taylor, O, 2015) |
| "To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide." | 7.73 | Nonconvulsive status epilepticus due to ifosfamide. ( Akoglu, H; Aksoy, S; Cakar, M; Erman, M; Kilickap, S; Onal, IK; Tekuzman, G; Tufan, A, 2006) |
| "Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide." | 7.69 | Hallucinations and ifosfamide-induced neurotoxicity. ( Baile, WF; Brown, R; DiMaggio, JR; Schapira, D, 1994) |
| "We examined the possibility of continuing oxazaphosphorine therapy in patients with previously documented cyclophosphamide- or ifosfamide-induced hematuria by concomitant use of the uroprotective agent, mesna." | 7.67 | The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. ( Andriole, GL; Arasi, V; Linehan, M; Magrath, IT; Miser, JS; Sandlund, JT, 1987) |
| "Ifosfamide and cisplatin cause urinary loss of carnitine, which is a fundamental molecule for energy production in mammalian cells." | 6.70 | Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. ( Baldelli, AM; Bisonni, R; Canestrari, F; Catalano, V; De Gaetano, A; Ferraro, B; Giordani, P; Graziano, F; Lai, V; Mencarini, E; Rovidati, S; Silva, R; Testa, E, 2002) |
| "Mucositis is a common toxicity of cancer chemotherapy." | 6.68 | Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. ( Anderson, PM; Skubitz, KM, 1996) |
| "Ondansetron is a 5-HT3 antagonist and its antiemetic properties have been established in adults receiving chemotherapy." | 6.67 | The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. ( Hewitt, M; McQuade, B; Stevens, R, 1993) |
| " Increased hydration and dosage of mesna are administered to patients who develop IFO-induced HC; they also receive 24-h continuous infusion of mesna in subsequent treatment cycles." | 5.43 | A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors. ( Kumamoto, T; Makino, Y; Ogawa, C; Saito, Y; Tamai, I; Terakado, H, 2016) |
| "Fatigue is the most frequent symptom experienced by children/adolescents with cancer." | 5.35 | Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. ( Gregurich, M; Hockenberry, MJ; Hooke, MC; McCarthy, K, 2009) |
| "To investigate the electronic anti-nausea instrument (EANI) combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy." | 5.19 | Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. ( Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014) |
| "The MSC cold cap system is effective in preventing alopecia from anthracycline, etoposide or taxane but not from anthracycline-taxane combinations or ifosfamide-containing regimens." | 5.10 | Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia. ( Christodoulou, C; Efstathiou, E; Klouvas, G; Papazachariou, E; Plyta, M; Skarlos, DV; Zervakis, D, 2002) |
| "From April 1993 to September 1993, 15 patients with lymphoid or solid neoplasms underwent 16 non-cryopreserved peripheral stem cell transplantation courses using the ICE (ifosfamide, carboplatin, etoposide) program." | 5.08 | Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. ( Aguilar-Ponce, L; Dueñas-Gonzalez, A; Frias-Mendivil, M; Gallardo-Rincon, D; Lara-Medina, F; Miranda-Lopez, E; Reynoso-Gomez, E; Sobrevilla-Calvo, P; Zinser-Sierra, J, 1996) |
| "Phase II studies conducted in Europe and the USA on pediatric solid tumors have shown that ifosfamide, as a single agent, is an active drug against a variety of neoplasms - rhabdomyosarcoma (RMS), some non-RMS soft tissue sarcomas, Wilms' tumor, bone sarcomas and neuroblastoma." | 4.82 | Ifosfamide in pediatric solid tumors. ( Bisogno, G; Carli, M; Passone, E; Perilongo, G, 2003) |
| "This article gives highlights of ongoing pediatric solid tumor and leukemia trials in the United States that use ifosfamide in combination with mesna." | 4.79 | Ongoing clinical studies of ifosfamide for pediatric cancer in the United States. ( Pratt, CB, 1996) |
| "Patients who developed gastrointestinal bleeding/ulcer were treated concurrently with vincristine-cyclophosphamide-ifosfamide-etoposide or vincristine-cyclophosphamide, and their ages were older than those of patients without gastrointestinal bleeding/ulcer." | 4.31 | Gastrointestinal bleeding/ulcer among paediatric cancer patients after proton beam therapy. ( Fukushima, H; Hosaka, S; Inaba, M; Masumoto, K; Mizumoto, M; Muroi, A; Okunushi, T; Sakurai, H; Suzuki, R; Tagawa, M; Takada, H; Watanabe, A; Yamaki, Y, 2023) |
| " Measurements included carnitine plasma levels and self-reported fatigue using established child or adolescent fatigue scales and were collected during the 2nd cycle of chemotherapy, and repeated on alternating cycles up to cycle 8." | 3.81 | Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents. ( Hockenberry, MJ; Hooke, MC; McCarthy, K; Taylor, O, 2015) |
| "Ifosfamide is an alkylating agent used in the treatment of germ-cell tumors, sarcomas and lymphomas." | 3.73 | [Ifosfamide induced encephalopathy: 15 observations]. ( Behar, C; Dufour, C; Grill, J; Hartmann, O; Motte, J; Munzer, M; Oberlin, O; Paci, A; Sabouraud, P, 2006) |
| "To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide." | 3.73 | Nonconvulsive status epilepticus due to ifosfamide. ( Akoglu, H; Aksoy, S; Cakar, M; Erman, M; Kilickap, S; Onal, IK; Tekuzman, G; Tufan, A, 2006) |
| "To evaluate proteinuria occurring early after ifosfamide therapy and to assess the use of changes in proteinuria in the prediction of severe chronic nephrotoxicity." | 3.70 | Acute changes in urine protein excretion may predict chronic ifosfamide nephrotoxicity: a preliminary observation. ( English, M; Hall, AG; MacLean, FR; Pearson, AD; Skinner, R, 1998) |
| "Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide." | 3.69 | Hallucinations and ifosfamide-induced neurotoxicity. ( Baile, WF; Brown, R; DiMaggio, JR; Schapira, D, 1994) |
| "We examined the possibility of continuing oxazaphosphorine therapy in patients with previously documented cyclophosphamide- or ifosfamide-induced hematuria by concomitant use of the uroprotective agent, mesna." | 3.67 | The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. ( Andriole, GL; Arasi, V; Linehan, M; Magrath, IT; Miser, JS; Sandlund, JT, 1987) |
| " We conducted a phase 1 trial to evaluate the safety of olaratumab and determine a recommended dose in combination with three different chemotherapy regimens in children." | 3.01 | Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. ( Bishop, MW; Borinstein, SC; DuBois, SG; Hingorani, P; Krystal, J; Laetsch, TW; Levy, DE; Mascarenhas, L; Mo, G; Muscal, JA; Ogawa, C; Shahir, A; Slotkin, EK; Weigel, BJ; Wright, J, 2021) |
| "IFO-induced encephalopathy (IIE) is one of the serious side effects, but there is not enough evidence regarding the clinical features of IIE in children." | 2.90 | Analysis of the clinical characteristics of pediatric patients who experience ifosfamide-induced encephalopathy. ( Honda, T; Ide, Y; Kubota, N; Nakamura, T; Sakashita, K; Tozuka, M; Yanagisawa, R, 2019) |
| " We conducted a dose-finding and pharmacokinetic (PK)/pharmacodynamics study of pazopanib combined with two different schedules of ifosfamide." | 2.79 | Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study. ( Boers-Sonderen, MJ; de Bruijn, P; Eskens, FA; Hamberg, P; Sleijfer, S; Suttle, AB; van der Graaf, WT; van Herpen, CM; Verweij, J, 2014) |
| "Topotecan AUC was significantly correlated with time to platelet recovery." | 2.76 | Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates. ( Dawson, JL; Field, TL; Fields, KK; Goldstein, SC; Kim, J; Lush, RM; Maddox, BL; Neuger, AM; Partyka, JS; Perkins, JB; Simonelli, CE; Sullivan, DM, 2011) |
| " Pharmacokinetic analysis revealed a linear relation between the area under the concentration-versus-time curve (AUC) and dose." | 2.75 | Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors. ( Akashi, Y; Fukuoka, M; Miyazaki, M; Nakagawa, K; Okamoto, I; Ozaki, T; Satoh, T; Shimizu, T; Tamura, K, 2010) |
| " Pharmacokinetic (PK) and pharmacodynamic (PD) assessments were performed." | 2.75 | Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies. ( den Hollander, M; Gelderblom, H; Hamberg, P; Loos, WJ; Sleijfer, S; Steeghs, N; Tascilar, M; van de Biessen, D; Verweij, J, 2010) |
| "Cancer patients with solid tumors that experienced post chemotherapy thrombocytopenia with a nadir of < = 80,000 platelets/ml were eligible for this clinical trial." | 2.75 | Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia. ( Daehler, M; Grutsch, JF; Gupta, D; Hall, JL; Levin, RD; Lis, CG, 2010) |
| "Paclitaxel was administered as a 6-hr continuous infusion (hr 0-6), followed by intravenous ifosfamide (2 g/m(2)/day x 3 days) over 1 hr at hours 6-7, 24-25, and 48-49." | 2.74 | Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). ( Bernstein, M; Blaney, SM; Geller, JI; Perentesis, J; Wall, D, 2009) |
| "Ifosfamide (IFOS) is a bifunctional alkylator with a wide spectrum of activity in solid tumors and has an autoinductive liver metabolism through P450 cytochromes." | 2.73 | An original administration of ifosfamide given once every other week: a clinical and pharmacological study. ( Alexandre, J; Cacheux, W; Duffau, B; Germann, N; Goldwasser, F; Gourmel, B; Rabillon, F, 2008) |
| "The grade of oral mucositis was assessed by the WHO per NCI-CTC common toxicity criteria and the assessments were made on days 1, 8 and 15 by a trained examiner blind to the intervention." | 2.73 | Influence of low-energy laser in the prevention of oral mucositis in children with cancer receiving chemotherapy. ( Brunetto, AL; Castro, CG; Cruz, LB; Rech, A; Ribeiro, AS; Rosa, LG, 2007) |
| " The peak concentration and area under the curve (AUC) were determined for the parent compound and the metabolites 4-hydroxyifosfamide and chloracetaldehyde in eight patients who received two cycles of ICE chemotherapy (ifosfamide 5 g/m(2) day 1, carboplatin 300 mg/m(2) day 1, etoposide 100 mg/m(2) days 1-3)." | 2.73 | Influence of short-term use of dexamethasone on the pharmacokinetics of ifosfamide in patients. ( Brüggemann, SK; Peters, SO; Pfäffle, S; Wagner, T, 2007) |
| " The pharmacodynamic effects of mesna on depleting plasma cysteine, a GSH precursor, were evaluated in 22 patients as part of a Phase I study." | 2.71 | Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion. ( Booker, BM; Creaven, P; Pendyala, L; Perez, R; Smith, PF, 2003) |
| "Ifosfamide was administered at a fixed dose of 1." | 2.71 | Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. ( Ambaum, B; Beijnen, JH; Groenewegen, G; Herben, VM; Jansen, S; Kerbusch, T; Mathôt, RA; Rosing, H; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; Voest, EE, 2004) |
| " Increases in mesna excretion after oral dosing lagged by 2-4 h." | 2.71 | Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children. ( Bush, DA; Epelman, S; Goren, MP, 2004) |
| " After adjusting for body size, AUC0-6 and Cmax were positively related to dose (P = 0." | 2.71 | Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. ( Beane, C; Boddy, AV; Brennan, B; Chisholm, JC; Cole, M; Elsworth, AM; Errington, J; Glaser, A; Hale, J; Hemsworth, S; Howe, K; Jenner, G; McDowell, H; Nicholson, J; Parry, A; Pearson, AD; Pinkerton, R; Pritchard-Jones, K; Veal, GJ; Waters, F; Wright, Y, 2005) |
| "Etoposide was administered on Days 1 and 2 (150 mg/m(2))." | 2.70 | Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. ( Baruchel, S; Fouladi, M; Gammon, J; Grant, R; Greenberg, ML; Klein, J; Koren, G; Stempak, D, 2001) |
| "Ifosfamide was administered by intravenous infusion over 3 h immediately followed by a 30-min infusion of topotecan." | 2.70 | Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors. ( Grübner, U; Höffken, K; Hoffmann, A; Kath, R; Merkel, U; Schneider, CP, 2002) |
| "Ifosfamide and cisplatin cause urinary loss of carnitine, which is a fundamental molecule for energy production in mammalian cells." | 2.70 | Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. ( Baldelli, AM; Bisonni, R; Canestrari, F; Catalano, V; De Gaetano, A; Ferraro, B; Giordani, P; Graziano, F; Lai, V; Mencarini, E; Rovidati, S; Silva, R; Testa, E, 2002) |
| " Pharmacokinetic studies were performed on day 1 of the first course in 33 patients and repeated on day 14 in 13 patients (once-daily schedule only)." | 2.69 | Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy. ( Arnold, B; Furman, WL; Garrison, L; Hanna, R; Luo, X; Marina, N; Meyer, WH; Pratt, CB; Rodman, JH; Tonda, ME, 1998) |
| "Paclitaxel was given after the first dose of ifosfamide on Day 1." | 2.69 | A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors. ( Berkowitz, R; Bunnell, CA; Buswell, L; Muto, M; Sheets, E; Shulman, LN; Thompson, L, 1998) |
| "Ifosfamide is an alkylating drug that has demonstrated activity against non-small cell lung cancer, testicular cancer, breast cancer, and soft tissue sarcoma." | 2.69 | Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study. ( de Bruijn, EA; Groult, V; Locci-Tonelli, D; Planting, AS; Pronk, LC; Schellens, JH; Schrijvers, D; van Oosterom, AT; Verweij, J, 1998) |
| " Effective modulatory doses of etanidazole could not be given with acceptable toxicity using this schedule." | 2.69 | Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support. ( Antman, KH; Ayash, LJ; Coleman, N; Elias, AD; Frei, E; Ibrahim, J; McCauley, M; Mills, L; Schnipper, L; Schwartz, G; Teicher, BA; Warren, D; Wheeler, C, 1998) |
| "Breast cancer patients treated with the VIPE regimen (including pretreated women) had a significantly higher CFU-GM rate than patients treated with EC (P=0." | 2.69 | Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells. ( Blumenstengel, K; Fricke, HJ; Höffken, K; Kath, R; Kunert, C; Sayer, HG; Vogel, W, 1998) |
| "Poor-risk solid tumors were treated with four courses of cyclophosphamide (4,200 mg/m2)/ doxorubicin (75 mg/m2), and three courses of ifosfamide (9,000 mg/m2)/etoposide (500 mg/m2)." | 2.69 | High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. ( Bajorin, D; Cheung, NK; Heller, G; Kramer, K; Kushner, BH; Meyers, PA; Polyak, T; Wollner, N, 1998) |
| "Thirty-one patients with solid tumors stratified according to pretreatment were randomized to receive cisplatin/ifosfamide-based chemotherapy with or without amifostine (1000 mg absolute) given as a short infusion prior to cisplatin." | 2.69 | The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors. ( Bokemeyer, C; Fels, LM; Hartmann, JT; Kanz, L; Knop, S; Stolte, H; van Vangerow, A, 2000) |
| "Ifosfamide and mesna were infused over 24 and 36 h, respectively, at equal daily doses; carboplatin was given after ifosfamide to a target plasma area under the curve of 4 mg x min x ml(-1)." | 2.69 | Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione. ( Bolanowska-Higdon, W; Creaven, PJ; Meropol, NJ; Murphy, M; Pendyala, L; Perez, R; Schwartz, G; Zdanowicz, J, 2000) |
| "Thirty-one patients with solid tumors stratified according to pretreatment were randomized to receive VIP- or TIP-chemotherapy with or without amifostine (910 mg/m2) given as a short infusion prior to cisplatin." | 2.69 | A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. ( Bokemeyer, C; Fels, LM; Hartmann, JT; Kanz, L; Knop, S; Stolt, H, 2000) |
| "Mucositis is a common toxicity of cancer chemotherapy." | 2.68 | Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. ( Anderson, PM; Skubitz, KM, 1996) |
| "The purpose of this phase I study is to determine the maximally tolerated doses of paclitaxel and carboplatin (dosed by area under the concentration-time curve) when given at specified times in combination with 6 g/m2 ifosfamide (3 g/m2 at 8 AM on days 1 and 2) with mesna and 5 microg/kg/d filgrastim (from day 4 until the absolute neutrophil count is > 10,000/microL) every 21 days for six cycles." | 2.68 | Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results. ( Palackdharry, CS, 1996) |
| "Patients with metastatic cancers were treated with GM-CSF at 5 micrograms/kg sc, days 1 to 7; leukaphereses were performed on days 6 and 7." | 2.68 | Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor. ( Balcerzak, SP; Benzies, T; Triozzi, PL; Tucker, F, 1996) |
| " Plasma ifosfamide concentrations were assayed by gas liquid chromatography and pharmacokinetic parameters were imputed using non-compartmental analysis." | 2.68 | A study of 5 day fractionated ifosfamide pharmacokinetics in consecutive treatment cycles. ( Lewis, LD, 1996) |
| "Etoposide has reported synergism with these alkylators and produces mucositis as its dose-limiting toxicity." | 2.67 | High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions. ( Antman, KH; Ayash, LJ; Elias, AD; Frei, E; Mazanet, R; McCauley, M; Schnipper, L; Schwartz, G; Tepler, I; Wheeler, C, 1994) |
| "The tolerance for and activity of escalating targeted doses of carboplatin combined with ifosfamide and etoposide (ICE) were assessed in children with advanced germ cell tumors or other rare solid tumors for which no standard therapy exists." | 2.67 | Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors. ( Bowman, LC; Furman, W; Jones, DP; Marina, NM; Meyer, WH; Murry, DJ; Pratt, CB; Rodman, JH; Shema, SJ, 1994) |
| "Ondansetron is a 5-HT3 antagonist and its antiemetic properties have been established in adults receiving chemotherapy." | 2.67 | The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. ( Hewitt, M; McQuade, B; Stevens, R, 1993) |
| "A continuous 14-day infusion of ifosfamide admixed with carboplatin is feasible in an ambulatory setting with no need for adding mesna for urologic protection and full dosage administration for each agent." | 2.67 | Pilot study of ambulatory infusional ifosfamide admixed with carboplatin. ( Anderson, NR; Bern, MM; Coco, F; Gonzalves, L; Lokich, JJ; Moore, C; Zipoli, TE, 1993) |
| "The tolerance of escalating targeted doses of carboplatin combined with ifosfamide (IFOS)/etoposide (VP-16) (ICE) was assessed in children with recurrent solid tumors." | 2.67 | Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. ( Bowman, LC; Douglass, E; Furman, W; Hudson, M; Marina, NM; Meyer, W; Rodman, J; Santana, VM; Shema, SJ; Wilimas, J, 1993) |
| "Patients were assigned to dosage cohorts separately on the basis of prior exposure to the platinum alkylating agents cisplatin or carboplatin (n = 20) or the absence of such exposure (n = 9)." | 2.67 | A phase I study of ifosfamide with Mesna given daily for 3 consecutive days to children with malignant solid tumors. ( Avery, L; Bowman, L; Douglass, EC; Marina, N; Meyer, WH; Ochs, J; Pratt, CB; Thompson, EI; Wilimas, J, 1993) |
| "Nephrotoxicity is an important adverse effect of chemotherapy in children." | 2.67 | The influence of age on nephrotoxicity following chemotherapy in children. ( Coulthard, MG; Craft, AW; Pearson, AD; Price, L; Skinner, R, 1992) |
| " Independent of the route of ifosfamide application on day 1, the terminal half-life on day 3 (when the drug was given by the alternative route) was decreased in 6 out of the 12 patients, thus indicating self-induction of hepatic metabolism." | 2.67 | Metabolism and pharmacokinetics of oral and intravenous ifosfamide. ( Cerny, T; Küpfer, A; Kurowski, V; Wagner, T, 1991) |
| "In this phase I study, 16 adult cancer patients were treated with concurrent 4-day continuous infusions of ifosfamide at 12 g/m2 and escalating doses of carboplatin (400-1600 mg/m2) to determine the major non-haematological dose-limiting toxicity of the combination." | 2.67 | Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study. ( Ayash, LJ; Critchlow, J; Deary, J; Eder, JP; Elias, AD; Frei, E; Hunt, M; Schnipper, L; Weissman, L; Wheeler, C, 1991) |
| "Thirty six patients with advanced solid tumors (24 lung: 3 oat-cell, 14 squamous, 7 adenocarcinomas, 3 soft tissue sarcomas, 6 breast carcinomas; 1 seminoma; 2 ovarian adenocarcinomas) entered a phase II study of high-dose ifosfamide (IF) administered in combination with the uroprotective agent sodium 2-mercapto-ethane-sulfonate (Mesna)." | 2.65 | Phase II study of ifosfamide combined with Mesna uroprotection in advanced non-small-cell lung carcinoma and other solid tumors. ( Brema, F; Cinquegrana, A; Nobile, MT; Rosso, R; Santi, L, 1984) |
| " A daily dosage of 50 to 60 mg/kg ifosfamide on 5 consecutive days produced the best results." | 2.64 | Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide. ( Brock, N; Burkert, H; Fichtner, E; Schnitker, J, 1976) |
| "Overall, childhood cancer survivors have a ninefold higher risk of developing renal failure compared with their siblings." | 2.58 | Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance. ( Skinner, R, 2018) |
| "Since CPA and IFO are widely used anticancer drugs, their efficacy is limited not only by their toxicity but also due to occurring resistance." | 2.49 | [Classical oxazaphosphorines--metabolism and therapeutic properties--new implications]. ( Górska, A; Hładoń, B; Misiura, K; Sikorska, M; Sloderbach, A, 2013) |
| "An assessment of the anticancer potential of glufosfamide is of key importance in therapy." | 2.47 | Glufosfamide as a new oxazaphosphorine anticancer agent. ( Mazur, L; Opydo-Chanek, M; Stojak, M, 2011) |
| "Ifosfamide is an important part of chemotherapeutic regimens used to treat a variety of malignancies." | 2.43 | Evaluating risk factors for the development of ifosfamide encephalopathy. ( David, KA; Picus, J, 2005) |
| "Several anticancer drugs have been added to the therapeutic armamentarium in recent years." | 2.42 | New chemotherapy agents in veterinary medicine. ( Kitchell, BE; Moore, AS, 2003) |
| "Ifosfamide is an alkylating agent used in the treatment of a variety of solid tumours." | 2.41 | Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. ( De Vos, F; Pelgrims, J; Prové, A; Schrijvers, D; Van den Brande, J; Vermorken, JB, 2000) |
| "Ifosfamide is an active drug for various tumors with elevated incidence in the elderly." | 2.41 | Ifosfamide in the elderly: clinical considerations for a better drug management. ( Catania, C; Comandone, A; Curigliano, G; de Braud, F; De Pas, T, 2000) |
| "Several commonly used cancer chemotherapeutic prodrugs, including cyclophosphamide and ifosfamide, are metabolized in the liver by a cytochrome P450 (CYP)-catalyzed prodrug activation reaction that is required for therapeutic activity." | 2.41 | Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. ( Chen, L; Waxman, DJ, 2002) |
| "Ifosfamide is an active drug in the therapy of paediatric tumours such as rhabdomyosarcoma, Ewings' sarcoma, Wilms' tumour, neuroblastoma, germ cell tumours and lymphomas." | 2.40 | The role of ifosfamide in paediatric cancer. ( Advani, SH, 1998) |
| "Nephrotoxicity is a relatively common and potentially serious adverse effect of treatment with certain cytotoxic drugs (especially ifosfamide)." | 2.39 | Strategies to prevent nephrotoxicity of anticancer drugs. ( Skinner, R, 1995) |
| "Chiral anticancer agents which exist as a pair of enantiomers are commonly administered as racemic (50:50) mixtures of the two isomers." | 2.38 | Stereoisomers in clinical oncology: why it is important to know what the right and left hands are doing. ( Wainer, IW, 1993) |
| "Ifosfamide is an effective drug for the treatment of solid tumors in children and most blastomas and sarcomas react favorably." | 2.38 | Ifosfamide in pediatric oncology. ( de Kraker, J; Voûte, PA, 1992) |
| "Ifosfamide is an oxazaphosphorine alkylating agent with a broad spectrum of antineoplastic activity." | 2.38 | Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. ( Brogden, RN; Dechant, KL; Faulds, D; Pilkington, T, 1991) |
| " Recent clinical trials suggest that oral mesna has adequate bioavailability (roughly 50% by urinary thiol measurements) to prevent urotoxicity in high-dose ifosfamide regimens." | 2.38 | Chemoprotectants for cancer chemotherapy. ( Dorr, RT, 1991) |
| "Mesna may produce gastrointestinal and allergic reactions." | 2.38 | Ifosfamide and mesna. ( Dana, WJ; Schoenike, SE, 1990) |
| "In germ cell tumors, the combination of ifosfamide and etoposide has proved to be an effective salvage regimen in patients resistant to vinblastine, bleomycin, and cisplatin." | 2.38 | Ifosfamide in pediatric malignancies. ( Göbel, U; Jürgens, H; Treuner, J; Winkler, K, 1989) |
| " Concerns about excessive toxicity-as many are infants and/or undergo nephrectomy-have resulted in decreased chemotherapy dosing and omission of the nephrotoxic drug ifosfamide in collaborative group studies." | 1.91 | Tolerability of ifosfamide-containing regimen in patients with high-risk renal and INI-1-deficient tumors. ( Benedetti, DJ; Kao, PC; Ma, C; Marcus, KJ; Mullen, EA; Wong, CI, 2023) |
| "In addition, polyploidy of TEC was observed to correlate with loss of lysozyme staining." | 1.91 | Cellular senescence in kidney biopsies is associated with tubular dysfunction and predicts CKD progression in childhood cancer patients with karyomegalic interstitial nephropathy. ( Broekhuizen, R; Goldschmeding, R; Haveman, LM; Janssens, GO; Keijzer-Veen, MG; Knoppert, SN; Lilien, MR; Nguyen, TQ; Stokman, MF; Valentijn, FA; van den Berg, G; van den Heuvel-Eibrink, MM; van Kempen, S, 2023) |
| "Ifosfamide is an antitumor agent with activity against various malignancies in pediatric patients." | 1.72 | Excellent Tolerability of Ifosfamide and Mesna Via Continuous Infusion in a Pediatric Patient Population. ( Anderson, PM; Pierson, CE; Plutt, AA; Stanton, MP; Zahler, S; Zembillas, AS, 2022) |
| "this study suggests that chemotherapy drug and its cumulative dosage has the most influence on kidney and urinary tract related complications." | 1.72 | Chemotherapy induced kidney and urinary tract related complications: A study in the Department of Pediatric Oncology and Hematology. ( Kiaunytė, S; Kiudelienė, R; Maškė, R; Rutkauskienė, G, 2022) |
| "Ifosfamide is an alkylating agent, mostly used against variety of solid tumors in pediatric oncology practice." | 1.62 | Ifosfamide-related encephalopathy with severe clinical presentations in children with cancer. ( Ataseven, E; Göktepe, ŞÖ; Kantar, M, 2021) |
| "Ifosfamide-related encephalopathy commonly results in a distinct pattern of generalized periodic discharges admixed with intermittent background attenuation on EEG." | 1.51 | Clinical and EEG Characteristics of Ifosfamide-Related Encephalopathy. ( Chen, X; Gusdon, AM; Malani, R, 2019) |
| "Childhood cancer survivors treated with cisplatin, ifosfamide, or carboplatin are at risk for late kidney and blood pressure (BP) abnormalities." | 1.48 | Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study. ( Harel-Sterling, M; Hessey, E; Huynh, L; McMahon, KR; Pizzi, M; Zappitelli, M, 2018) |
| " Those results are in agreement with literature data reporting that intracellular CAA toxic concentrations range from 35 to 320 μM, after therapeutic ifosfamide dosing." | 1.43 | Investigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models. ( Bois, FY; Hamon, J; Leclerc, E, 2016) |
| " Patients with encephalopathy and patients without encephalopathy were compared on age, Eastern Cooperative Oncology Group (ECOG) performance status (PS), baseline serum creatinine (SCr) level, albumin level, white blood cell count, liver function, brain metastasis, and dosage of ifosfamide." | 1.43 | Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: A retrospective analysis. ( Chen, WH; Dong, YH; Lo, Y; Shen, LJ; Wu, FL, 2016) |
| " Increased hydration and dosage of mesna are administered to patients who develop IFO-induced HC; they also receive 24-h continuous infusion of mesna in subsequent treatment cycles." | 1.43 | A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors. ( Kumamoto, T; Makino, Y; Ogawa, C; Saito, Y; Tamai, I; Terakado, H, 2016) |
| "Pediatr Blood Cancer 2015;62:274-278." | 1.40 | ( Adiguzel, R; Andreana, PR; Arslan, Z; Ates, M; Bemis, T; Bercovitch, LG; Bögli, S; Boucherez, J; Boudouf, S; Briat, JF; Brown, BM; Busemann, A; Buters, J; Byers, JS; Cairo, MS; Carrier, F; Chalmers, JJ; Chang, E; Chen, J; Chen, Y; Christenson, MK; Cielecka-Piontek, J; Cole, PA; Cooper, BS; Davis, PH; De Silva, RA; Decato, S; DeFries, RS; Demir, V; Denic, A; Deserno, M; Dickey, AM; Diss, E; Eberlein, B; Eyerich, S; Faluvegi, G; Farlow, MR; Fletcher, JW; Francetic, T; Furlan, L; Garbacki, P; Gartung, A; Garvin, JH; Gates, L; Gaymard, F; Ghetti, B; Gibson, MP; Griffin, RG; Hamed, M; Hammad, LA; Hammond, GB; Han, J; Hann, R; Hao, N; Harrison, LA; Heidecke, CD; Hutchins, GD; Inlow, M; Irmer, H; Jani, P; Jara-Cavieres, A; Jawadi, H; Jiang, Q; Jiang, Y; Kameda, T; Keeler, EG; Kim, H; Kim, R; Kim, S; Kinney, PL; Krause, A; Kumar, V; Kwok, Y; Lam, T; Lanni, F; Le May, M; Lee, A; Lee, JF; Lee, MJ; Leontyev, IV; Li, Q; Li, X; Liu, J; Liu, NK; Lominadze, D; Lösche, M; Lu, QB; Lu, Y; Lu, Z; Mach, H; Madsen, E; Marletta, M; Marlier, ME; McDonald, BC; McKay, IS; Mckenzie, CL; Mecozzi, S; Menges, P; Meyers, D; Michaelis, VK; Montooth, KL; Moore, LR; Morgan, JK; Morris, E; Movahed, M; Nalabothula, N; Narayanan, S; Nguyen, D; Nho, K; Oken, B; Ong, TC; Osborne, LS; Paczkowska, M; Park, EK; Pennino, D; Peters, S; Potluri, LP; Qin, C; Radhakrishnan, K; Randerson, JT; Rantanen, J; Reyt, G; Ring, J; Risacher, SL; Rodriguez, M; Saykin, AJ; Schmidt-Weber, CB; Sengelaub, DR; Shatters, RG; Shen, L; Shen, V; Shindell, DT; Stuchebrukhov, AA; Swaminathan, S; Takahashi, K; Talaczyńska, A; Tallman, EF; Tan, C; Terry, SF; Trabbic, KR; Trease, AJ; Tretter, C; Uitto, J; Váradi, A; von Bernstorff, W; Voulgarakis, A; Wagenhofer, M; Wahbeh, H; Wang, EN; Wang, X; Wells, RJ; West, JD; Williams, PS; Wolff, JE; Wootla, B; Xu, B; Xu, XM; Yoder, KK; Zalewski, P; Zan, GH; Zborowski, M; Zhang, HH; Zhang, W; Zhao, J; Zoecklein, L, 2014) |
| "Data from 763 adult childhood cancer survivors (414 men) were obtained during regular visits at the late-effects clinic between 2003 and 2009." | 1.39 | Long-term nephrotoxicity in adult survivors of childhood cancer. ( Blijdorp, K; Cransberg, K; Dekkers, IA; Neggers, SJ; Pieters, R; Pluijm, SM; van den Heuvel-Eibrink, MM, 2013) |
| "Nephrotoxicity is a serious side effect associated with ifosfamide use." | 1.39 | N-acetylcysteine rescue protocol for nephrotoxicity in children caused by ifosfamide. ( Hanly, L; Huang, SH; Koren, G; Regueira, O; Rieder, MJ; Shah, RK; Vasylyeva, TL, 2013) |
| "Patients with hematologic or solid tumors who underwent conditioning regimen were asked to score mucositis severity daily from the first day to the tenth day of reinfusion." | 1.35 | Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation. ( Arpaci, F; Ataergin, S; Kilic, S; Komurcu, S; Kuzhan, O; Ozet, A; Ozturk, B; Ozturk, M, 2009) |
| "Fatigue is the most frequent symptom experienced by children/adolescents with cancer." | 1.35 | Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. ( Gregurich, M; Hockenberry, MJ; Hooke, MC; McCarthy, K, 2009) |
| "Ifosfamide was dosed either as a continuous infusion or as fractionated doses over 2 or 3 days." | 1.33 | Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. ( Boddy, AV; Cholerton, S; Ford, D; Parry, A; Pearson, AD; Price, L; Tilby, MJ; Willits, I, 2005) |
| "9L/2B6 tumors regressed more slowly and exhibited a tumor-free period of only 21 to 39 days." | 1.33 | Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11. ( Chen, CS; Jounaidi, Y; Veal, GJ; Waxman, DJ, 2006) |
| "Despite the continuous improvement of cancer treatment protocols, altered testicular function and infertility frequently represent major adverse effects of oncologic treatments." | 1.33 | Progress in the development of childhood cancer therapy. ( Carli, MO; Ferlin, A; Foresta, C; Garolla, A; Pizzato, C; Selice, R, 2006) |
| "The aim of the study was an assessment of various risk factors for nephrotoxicity of ifosfamide (IF) in children taking into account the importance of the concentrations of toxic metabolites of the drug excreted with urine and the polymorphism of genes encoding S-glutathione transferases of mi, pi, and theta classes (GSTM1, GSTP1 and GSTT1)." | 1.32 | [Polymorphism at the glutathione S-transferase pi locus as a risk factor for ifosfamide nephrotoxicity in children]. ( Bodalski, J; Zielińska, E; Zubowska, M, 2003) |
| "08) and dosage (median 2." | 1.32 | Incidence and severity of ifosfamide-induced encephalopathy. ( Fiegl, M; Ostermann, H; Rieger, C; Schiel, X; Tischer, J, 2004) |
| "The renal functions in pediatric cancer patients who received ifosfamide (IFO) treatment were evaluated and the risk factors related to IFO nephrotoxicity were determined." | 1.31 | Ifosfamide nephrotoxicity in pediatric cancer patients. ( Ahn, HS; Cheong, HI; Choi, Y; Ha, IS; Hahn, H; Kang, HG; Lee, BS; Lee, JH; Shin, HY, 2001) |
| " In this study, we investigated the toxic effects of ifosfamide and cisplatin by clinical and biochemical parameters in relation to (99m)Tc-dimercaptosuccinic acid ((99m)Tc-DMSA) and Tc(99m)N, N-ethylenedicysteine (EC) renal scintigraphy." | 1.31 | The utility of (99m)Tc-DMSA and Tc(99m)-EC scintigraphy for early diagnosis of ifosfamide induced nephrotoxicity. ( Akyuz, C; Caglar, M; Yarís, N, 2001) |
| "Ifosfamide is an analogue of cyclophosphamide active in the treatment of numerous tumours." | 1.30 | 6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies. ( Alexandre, J; Brain, EC; Chaouche, M; Cvitkovic, E; Delord, JP; Errihani, H; Hardy Bessard, AC; Jasmin, C; Misset, JL; Mita, A; Soulié, P, 1997) |
| " The kinetics of the excretion were compared following short-term and continuous ifosfamide infusion at a dosage of 3 g/m2." | 1.30 | Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion. ( Blaschke, G; Boos, J; Hohenlöchter, B; Jürgens, H; Rossi, R; Silies, H, 1998) |
| "Ifosfamide is an oxazophosphorine widely used in the treatment of cancer in children and adults." | 1.30 | Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy. ( Foxall, PJ; Hartley, JM; Lapsley, M; Neild, GH; Nicholson, JK; Singer, JM; Souhami, RL, 1997) |
| "Five patients developed renal Fanconi syndrome during follow-up, and another seven patients developed a generalized subclinical tubulopathy." | 1.30 | Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients. ( Deufel, T; Jürgens, H; Kleta, R; Kuhn, N; Pleyer, J; Rossi, R; Schäfers, P, 1999) |
| " A critical question in comparing an experimental treatment to a standard is how much increase in an adverse event rate is an acceptable trade-off for achieving a targeted improvement in efficacy, or vice versa." | 1.30 | Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials. ( Cheng, SC; Thall, PF, 1999) |
| "IFM was a common agent among the anti-cancer agents used in these cases." | 1.29 | [Ventricular premature contraction observed after anti-cancer chemotherapy with ifosfamide]. ( Abe, Y; Fukuda, H; Kawashima, R; Kubota, K; Sato, T; Takahashi, J; Yamada, K, 1994) |
| "Paclitaxel was given at a dose of 120 mg/m2 to five patients, 135 mg/m2 to five patients, 150 mg/m2 to three patients, and 175 mg/m2 to 11 patients." | 1.29 | Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study. ( Asbury, RF; Boros, L; Chang, AY; Garrow, GC; Hui, L, 1996) |
| "The ifosfamide treatment schedules had only minimal effects on bromisoval pharmacokinetics." | 1.29 | Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers. ( Breimer, DD; Mulder, GJ; Mulders, TM; Ouwerkerk, J; van der Velde, EA, 1995) |
| "Thirty-two cancer patients were given a 1-day course of chemotherapy consisting of etoposide (VP16), ifosfamide, and cisplatin (VIP; n = 46 cycles), followed by the combined sequential administration of recombinant human interleukin-3 (rhIL-3) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF)." | 1.28 | Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. ( Bross, K; Brugger, W; Dern, P; Frisch, J; Kanz, L; Mertelsmann, R; Weber, B, 1992) |
| "Acute encephalopathy following treatment with ifosfamide and mesna was observed in 5 (4 women and 1 men) of 28 patients (17." | 1.28 | Encephalopathy in ifosfamide-treated patients. ( Chaitchik, S; Merimsky, O; Reider-Groswasser, I; Wigler, N, 1992) |
| "Ifosfamide is a newly available analog of cyclophosphamide in the oxazaphosphorine drug class." | 1.28 | Ifosfamide vs cyclophosphamide in cancer therapy. ( Weiss, RB, 1991) |
| " We have studied the feasibility and bioavailability of a subcutaneously (s." | 1.28 | Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility. ( Brunner, KW; Cerny, T; Graf, A; Küpfer, A; Rohner, P; Zeugin, T, 1991) |
| "When ifosfamide 5 g m-2 was given as a 24 h infusion, the decay of the plasma ifosfamide concentration was monoexponential, the median (range) t1/2,z was 4." | 1.28 | The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients. ( Fitzgerald, DL; Harper, PG; Lewis, LD; Mohan, P; Rogers, HJ; Thatcher, N, 1991) |
| "Ifosfamide has broad cytotoxicity against solid tumors and may prove to be an important addition to high-dose combination chemotherapy regimens." | 1.28 | High-dose ifosfamide with mesna uroprotection: a phase I study. ( Antman, KH; Begg, CB; Eder, JP; Elias, AD; Frei, E; Shea, T, 1990) |
| "Ifosfamide is an important alkylating agent that should be combined with other agents in phase II and III trials." | 1.28 | Ifosfamide in pediatric malignant solid tumors. ( Douglass, EC; Etcubanas, EL; Goren, MP; Green, AA; Hayes, FA; Horowitz, ME; Meyer, WH; Pratt, CB; Thompson, EI; Wilimas, JA, 1989) |
| "Ifosfamide has been shown to be an active agent in the treatment of several childhood cancers." | 1.28 | Toxicity of high-dose ifosfamide in children. ( Craft, AW; Davies, SM; Pearson, AD, 1989) |
| "One hundred and forty-six patients with advanced malignant disease were treated with 6 different dosage schedules of ifosfamide (IFX)." | 1.28 | Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector. ( Falkson, CI; Falkson, G; Falkson, HC, 1989) |
| "Ifosfamide (IFS) is a new alkylating oxazaphosphorine related to cyclophosphamide." | 1.28 | Ifosfamide cardiotoxicity in humans. ( Efremidis, AP; Kandylis, K; Tsoussis, S; Vassilomanolakis, M, 1989) |
| "The antitumor activity of ifosfamide in testicular cancer was not reduced by mesna." | 1.27 | Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients. ( Bremer, K; Niederle, N; Scheulen, ME; Schütte, J; Seeber, S, 1983) |
| "Ifosfamide/mesna treatment of 50 patients with pediatric malignant solid tumors was associated with the development of neurotoxic signs and symptoms in 11 of these individuals who received 29 courses of treatment." | 1.27 | Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. ( Douglass, E; Etcubanas, E; Green, AA; Hayes, FA; Horowitz, ME; Igarashi, M; Meyer, WH; Pratt, CB; Thompson, E; Wilimas, J, 1986) |
| "Ifosfamide was given to 61 patients with malignant solid tumors diagnosed before the age of 21 years." | 1.27 | Phase II trial of ifosfamide in children with malignant solid tumors. ( Douglass, EC; Etcubanas, E; Green, AA; Hayes, FA; Horowitz, ME; Meyer, WH; Pratt, CB; Thompson, EI; Wilimas, JA, 1987) |
| " Analysis of the results according to sex, age, dosage of ifosfamide and degree of histological differentiation of the tumour cells failed to show any influence of these factors on the therapeutic results." | 1.27 | Treatment of advanced malignancies with ifosfamide under protection with mesna. ( Brock, N; Guan, ZZ; He, YJ; Li, GC; Li, JQ, 1988) |
| "Thirty-two patients with advanced cancer were treated in a phase I-II trial with ifosfamide plus mesnum." | 1.26 | Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment. ( Falkson, G; Falkson, HC; Stapelberg, R; Van Dyk, JJ, 1982) |
| "153 patients with inoperable malignant tumors were treated by the so-called synchronization therapy with vincristine and ifosfamide." | 1.26 | [Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)]. ( Hartwich, G; Lutz, H; Neidhardt, B, 1978) |
| " Plasma half-life for ifosfamide given in the divided-dose schedule was 6." | 1.26 | Pharmacokinetics of divided-dose ifosfamide. ( Allen, LM; Creaven, PJ; Nelson, RL, 1976) |
| "Ifosfamide was given in i." | 1.26 | Reduction of ifosfamide toxicity using dose fractionation. ( Bodey, GP; Freireich, EJ; McCredie, KB; McKelvey, EM; Rodriguez, V; Tashima, CK, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 61 (22.10) | 18.7374 |
| 1990's | 110 (39.86) | 18.2507 |
| 2000's | 66 (23.91) | 29.6817 |
| 2010's | 31 (11.23) | 24.3611 |
| 2020's | 8 (2.90) | 2.80 |
| Authors | Studies |
|---|---|
| Plutt, AA | 1 |
| Stanton, MP | 1 |
| Zembillas, AS | 1 |
| Pierson, CE | 1 |
| Zahler, S | 1 |
| Anderson, PM | 2 |
| Kiaunytė, S | 1 |
| Maškė, R | 1 |
| Kiudelienė, R | 1 |
| Rutkauskienė, G | 1 |
| Fukushima, H | 1 |
| Mizumoto, M | 1 |
| Suzuki, R | 1 |
| Yamaki, Y | 1 |
| Hosaka, S | 1 |
| Inaba, M | 1 |
| Tagawa, M | 1 |
| Watanabe, A | 1 |
| Okunushi, T | 1 |
| Masumoto, K | 1 |
| Muroi, A | 1 |
| Sakurai, H | 1 |
| Takada, H | 1 |
| Wong, CI | 1 |
| Benedetti, DJ | 1 |
| Kao, PC | 1 |
| Ma, C | 1 |
| Marcus, KJ | 1 |
| Mullen, EA | 1 |
| Knoppert, SN | 1 |
| Keijzer-Veen, MG | 1 |
| Valentijn, FA | 1 |
| van den Heuvel-Eibrink, MM | 2 |
| Lilien, MR | 1 |
| van den Berg, G | 1 |
| Haveman, LM | 1 |
| Stokman, MF | 1 |
| Janssens, GO | 1 |
| van Kempen, S | 1 |
| Broekhuizen, R | 1 |
| Goldschmeding, R | 1 |
| Nguyen, TQ | 1 |
| Ide, Y | 1 |
| Yanagisawa, R | 1 |
| Kubota, N | 1 |
| Sakashita, K | 1 |
| Tozuka, M | 1 |
| Nakamura, T | 1 |
| Honda, T | 1 |
| Torres Espíndola, LM | 1 |
| Rojo-Serrato, D | 1 |
| Álvaro-Heredia, A | 1 |
| Castillejos López, MJ | 1 |
| de Uña-Flores, A | 1 |
| Pérez-García, M | 1 |
| Zapata-Tarres, M | 1 |
| Cárdenas-Cardos, R | 1 |
| Granados, J | 1 |
| Chávez-Pacheco, JL | 1 |
| Salinas-Lara, C | 1 |
| de Arellano, IT | 1 |
| Aquino-Gálvez, A | 1 |
| Mascarenhas, L | 1 |
| Ogawa, C | 2 |
| Laetsch, TW | 1 |
| Weigel, BJ | 1 |
| Bishop, MW | 1 |
| Krystal, J | 1 |
| Borinstein, SC | 1 |
| Slotkin, EK | 1 |
| Muscal, JA | 1 |
| Hingorani, P | 1 |
| Levy, DE | 1 |
| Mo, G | 1 |
| Shahir, A | 1 |
| Wright, J | 1 |
| DuBois, SG | 1 |
| Ataseven, E | 1 |
| Göktepe, ŞÖ | 1 |
| Kantar, M | 1 |
| Sterling, M | 1 |
| Al-Ismaili, Z | 1 |
| McMahon, KR | 2 |
| Piccioni, M | 1 |
| Pizzi, M | 2 |
| Mottes, T | 1 |
| Lands, LC | 1 |
| Abish, S | 1 |
| Fleming, AJ | 1 |
| Bennett, MR | 1 |
| Palijan, A | 1 |
| Devarajan, P | 1 |
| Goldstein, SL | 1 |
| O'Brien, MM | 1 |
| Zappitelli, M | 2 |
| Skinner, R | 8 |
| Ruggiero, A | 1 |
| Ferrara, P | 1 |
| Attinà, G | 1 |
| Rizzo, D | 1 |
| Riccardi, R | 1 |
| Harel-Sterling, M | 1 |
| Huynh, L | 1 |
| Hessey, E | 1 |
| Gusdon, AM | 1 |
| Malani, R | 1 |
| Chen, X | 1 |
| Dekkers, IA | 1 |
| Blijdorp, K | 1 |
| Cransberg, K | 1 |
| Pluijm, SM | 1 |
| Pieters, R | 1 |
| Neggers, SJ | 1 |
| Hanly, L | 1 |
| Rieder, MJ | 1 |
| Huang, SH | 1 |
| Vasylyeva, TL | 1 |
| Shah, RK | 1 |
| Regueira, O | 1 |
| Koren, G | 3 |
| Hartmann, JT | 3 |
| Horger, M | 1 |
| Kluba, T | 1 |
| Königsrainer, A | 1 |
| de Zwart, P | 1 |
| von Weyhern, CH | 1 |
| Eckert, F | 1 |
| Budach, W | 1 |
| Bokemeyer, C | 4 |
| Hamberg, P | 2 |
| Boers-Sonderen, MJ | 1 |
| van der Graaf, WT | 1 |
| de Bruijn, P | 1 |
| Suttle, AB | 1 |
| Eskens, FA | 1 |
| Verweij, J | 5 |
| van Herpen, CM | 1 |
| Sleijfer, S | 2 |
| Sloderbach, A | 1 |
| Górska, A | 1 |
| Sikorska, M | 1 |
| Misiura, K | 1 |
| Hładoń, B | 1 |
| Lowenberg, D | 1 |
| Thorn, CF | 1 |
| Desta, Z | 1 |
| Flockhart, DA | 1 |
| Altman, RB | 1 |
| Klein, TE | 1 |
| Wang, WQ | 1 |
| Zhang, ZH | 1 |
| Zhou, JP | 1 |
| Pang, H | 1 |
| Lü, HX | 1 |
| Xiao, Y | 1 |
| Liu, J | 2 |
| Liu, YC | 1 |
| Huang, XE | 1 |
| Guo, JX | 1 |
| Wei, W | 1 |
| Lam, CG | 1 |
| Furman, WL | 4 |
| Wang, C | 1 |
| Spunt, SL | 1 |
| Wu, J | 1 |
| Ivy, P | 1 |
| Santana, VM | 2 |
| McGregor, LM | 1 |
| Hooke, MC | 2 |
| McCarthy, K | 2 |
| Taylor, O | 1 |
| Hockenberry, MJ | 2 |
| Kameda, T | 1 |
| Takahashi, K | 1 |
| Kim, R | 1 |
| Jiang, Y | 1 |
| Movahed, M | 1 |
| Park, EK | 1 |
| Rantanen, J | 1 |
| Marlier, ME | 1 |
| DeFries, RS | 1 |
| Voulgarakis, A | 1 |
| Kinney, PL | 1 |
| Randerson, JT | 1 |
| Shindell, DT | 1 |
| Chen, Y | 1 |
| Faluvegi, G | 1 |
| Diss, E | 1 |
| Nalabothula, N | 1 |
| Nguyen, D | 1 |
| Chang, E | 1 |
| Kwok, Y | 1 |
| Carrier, F | 1 |
| Radhakrishnan, K | 1 |
| Lee, A | 1 |
| Harrison, LA | 1 |
| Morris, E | 1 |
| Shen, V | 4 |
| Gates, L | 1 |
| Wells, RJ | 1 |
| Wolff, JE | 1 |
| Garvin, JH | 1 |
| Cairo, MS | 7 |
| Eberlein, B | 1 |
| Hann, R | 1 |
| Eyerich, S | 1 |
| Pennino, D | 1 |
| Ring, J | 1 |
| Schmidt-Weber, CB | 1 |
| Buters, J | 1 |
| Dickey, AM | 1 |
| Trease, AJ | 1 |
| Jara-Cavieres, A | 1 |
| Kumar, V | 1 |
| Christenson, MK | 1 |
| Potluri, LP | 1 |
| Morgan, JK | 1 |
| Shatters, RG | 1 |
| Mckenzie, CL | 1 |
| Davis, PH | 1 |
| Osborne, LS | 1 |
| Francetic, T | 1 |
| Le May, M | 1 |
| Hamed, M | 1 |
| Mach, H | 1 |
| Meyers, D | 1 |
| Cole, PA | 1 |
| Chen, J | 1 |
| Li, Q | 1 |
| Zborowski, M | 1 |
| Moore, LR | 1 |
| Williams, PS | 1 |
| Chalmers, JJ | 1 |
| Cooper, BS | 1 |
| Hammad, LA | 1 |
| Montooth, KL | 1 |
| Bögli, S | 1 |
| Brown, BM | 1 |
| Marletta, M | 1 |
| Tretter, C | 1 |
| Wagenhofer, M | 1 |
| Leontyev, IV | 1 |
| Stuchebrukhov, AA | 1 |
| Ates, M | 1 |
| Demir, V | 1 |
| Adiguzel, R | 1 |
| Arslan, Z | 1 |
| Zan, GH | 1 |
| Tan, C | 1 |
| Deserno, M | 1 |
| Lanni, F | 1 |
| Lösche, M | 1 |
| Decato, S | 1 |
| Bemis, T | 1 |
| Madsen, E | 1 |
| Mecozzi, S | 1 |
| Trabbic, KR | 1 |
| De Silva, RA | 1 |
| Andreana, PR | 1 |
| Wahbeh, H | 1 |
| Oken, B | 1 |
| Uitto, J | 1 |
| Jiang, Q | 1 |
| Váradi, A | 1 |
| Bercovitch, LG | 1 |
| Terry, SF | 1 |
| Zhao, J | 1 |
| Lee, JF | 1 |
| Gartung, A | 1 |
| Jawadi, H | 1 |
| Zhang, W | 1 |
| Lominadze, D | 1 |
| Lee, MJ | 1 |
| Denic, A | 1 |
| Wootla, B | 1 |
| Zoecklein, L | 1 |
| Rodriguez, M | 1 |
| Kim, S | 1 |
| Nho, K | 1 |
| Risacher, SL | 1 |
| Inlow, M | 1 |
| Swaminathan, S | 1 |
| Yoder, KK | 1 |
| Shen, L | 1 |
| West, JD | 1 |
| McDonald, BC | 1 |
| Tallman, EF | 1 |
| Hutchins, GD | 1 |
| Fletcher, JW | 1 |
| Farlow, MR | 1 |
| Ghetti, B | 1 |
| Saykin, AJ | 1 |
| Reyt, G | 1 |
| Boudouf, S | 1 |
| Boucherez, J | 1 |
| Gaymard, F | 1 |
| Briat, JF | 1 |
| Hao, N | 1 |
| Zhang, HH | 1 |
| Gibson, MP | 1 |
| Jani, P | 1 |
| Wang, X | 1 |
| Lu, Y | 1 |
| Qin, C | 1 |
| Han, J | 1 |
| Lu, Z | 1 |
| Hammond, GB | 1 |
| Xu, B | 1 |
| Liu, NK | 1 |
| Byers, JS | 1 |
| Lam, T | 1 |
| Lu, QB | 1 |
| Sengelaub, DR | 1 |
| Xu, XM | 1 |
| von Bernstorff, W | 1 |
| Irmer, H | 1 |
| Menges, P | 1 |
| Peters, S | 1 |
| Heidecke, CD | 1 |
| Busemann, A | 1 |
| Li, X | 1 |
| Narayanan, S | 1 |
| Michaelis, VK | 1 |
| Ong, TC | 1 |
| Keeler, EG | 1 |
| Kim, H | 1 |
| McKay, IS | 1 |
| Griffin, RG | 1 |
| Wang, EN | 1 |
| Furlan, L | 1 |
| Paczkowska, M | 1 |
| Zalewski, P | 1 |
| Garbacki, P | 1 |
| Talaczyńska, A | 1 |
| Krause, A | 1 |
| Cielecka-Piontek, J | 1 |
| Leclerc, E | 2 |
| Hamon, J | 1 |
| Bois, FY | 1 |
| Lo, Y | 1 |
| Shen, LJ | 1 |
| Chen, WH | 1 |
| Dong, YH | 1 |
| Wu, FL | 1 |
| Saito, Y | 1 |
| Kumamoto, T | 1 |
| Makino, Y | 1 |
| Tamai, I | 1 |
| Terakado, H | 1 |
| Bali Prasad, B | 1 |
| Kumar, A | 1 |
| Singh, R | 1 |
| Cacheux, W | 1 |
| Gourmel, B | 1 |
| Alexandre, J | 2 |
| Germann, N | 1 |
| Rabillon, F | 1 |
| Duffau, B | 1 |
| Goldwasser, F | 1 |
| Geller, JI | 1 |
| Wall, D | 1 |
| Perentesis, J | 1 |
| Blaney, SM | 1 |
| Bernstein, M | 1 |
| Lu, H | 1 |
| Chen, CS | 2 |
| Waxman, DJ | 5 |
| Di Cataldo, A | 1 |
| Astuto, M | 1 |
| Rizzo, G | 1 |
| Bertuna, G | 1 |
| Russo, G | 1 |
| Incorpora, G | 1 |
| Ozturk, M | 1 |
| Komurcu, S | 1 |
| Kilic, S | 1 |
| Ozet, A | 1 |
| Arpaci, F | 1 |
| Ozturk, B | 1 |
| Kuzhan, O | 1 |
| Ataergin, S | 1 |
| Ridola, V | 1 |
| Fawaz, O | 1 |
| Aubier, F | 1 |
| Bergeron, C | 1 |
| de Vathaire, F | 1 |
| Pichon, F | 1 |
| Orbach, D | 1 |
| Gentet, JC | 1 |
| Schmitt, C | 1 |
| Dufour, C | 2 |
| Oberlin, O | 2 |
| Shimizu, T | 1 |
| Okamoto, I | 1 |
| Tamura, K | 1 |
| Satoh, T | 2 |
| Miyazaki, M | 1 |
| Akashi, Y | 1 |
| Ozaki, T | 1 |
| Fukuoka, M | 1 |
| Nakagawa, K | 1 |
| Gregurich, M | 1 |
| Specenier, P | 1 |
| Rasschaert, M | 1 |
| Van den Brande, J | 2 |
| Dyck, J | 1 |
| Schrijvers, D | 4 |
| Huizing, MT | 1 |
| Vermorken, JB | 2 |
| Parry, A | 3 |
| Price, L | 6 |
| Cole, M | 2 |
| Craft, AW | 5 |
| Pearson, AD | 9 |
| Giraud, B | 1 |
| Hebert, G | 1 |
| Deroussent, A | 1 |
| Veal, GJ | 3 |
| Vassal, G | 1 |
| Paci, A | 2 |
| Steeghs, N | 1 |
| Loos, WJ | 1 |
| van de Biessen, D | 1 |
| den Hollander, M | 1 |
| Tascilar, M | 1 |
| Gelderblom, H | 1 |
| Levin, RD | 1 |
| Daehler, M | 1 |
| Grutsch, JF | 1 |
| Hall, JL | 1 |
| Gupta, D | 1 |
| Lis, CG | 1 |
| Mazur, L | 1 |
| Opydo-Chanek, M | 1 |
| Stojak, M | 1 |
| Perkins, JB | 3 |
| Goldstein, SC | 2 |
| Dawson, JL | 1 |
| Kim, J | 1 |
| Field, TL | 1 |
| Partyka, JS | 1 |
| Fields, KK | 4 |
| Maddox, BL | 1 |
| Simonelli, CE | 1 |
| Neuger, AM | 1 |
| Lush, RM | 1 |
| Sullivan, DM | 1 |
| Lacombe, D | 1 |
| Choucha Snouber, L | 1 |
| Jacques, S | 1 |
| Monge, M | 1 |
| Legallais, C | 1 |
| Marx, G | 1 |
| Lewis, C | 1 |
| Hall, K | 1 |
| Levi, J | 1 |
| Ackland, S | 1 |
| Kozuka, T | 1 |
| Ikeda, K | 1 |
| Teshima, T | 1 |
| Kojima, K | 1 |
| Matsuo, K | 1 |
| Bessho, A | 1 |
| Sunami, K | 1 |
| Hiramatsu, Y | 1 |
| Maeda, Y | 1 |
| Noguchi, T | 1 |
| Yamamoto, K | 1 |
| Fujii, N | 1 |
| Imai, T | 1 |
| Takenaka, K | 1 |
| Shinagawa, K | 1 |
| Ishimaru, F | 1 |
| Niiya, K | 1 |
| Koide, N | 1 |
| Tanimoto, M | 1 |
| Harada, M | 1 |
| Niculescu-Duvaz, I | 1 |
| Baldwin, A | 1 |
| Huang, Z | 1 |
| Jounaidi, Y | 2 |
| Moore, AS | 1 |
| Kitchell, BE | 1 |
| Zielińska, E | 1 |
| Zubowska, M | 1 |
| Bodalski, J | 1 |
| Buesa, JM | 2 |
| García-Teijido, P | 1 |
| Losa, R | 2 |
| Fra, J | 1 |
| Carli, M | 1 |
| Passone, E | 1 |
| Perilongo, G | 1 |
| Bisogno, G | 1 |
| Smith, PF | 1 |
| Booker, BM | 1 |
| Creaven, P | 1 |
| Perez, R | 2 |
| Pendyala, L | 2 |
| Kempgens, B | 1 |
| Kisro, J | 1 |
| Gruber, Y | 1 |
| Bahrs, H | 1 |
| Wagner, T | 5 |
| Loss, JF | 1 |
| Santos, PP | 1 |
| Leone, LD | 1 |
| Brunetto, AL | 2 |
| Rieger, C | 1 |
| Fiegl, M | 1 |
| Tischer, J | 1 |
| Ostermann, H | 1 |
| Schiel, X | 1 |
| Kerbusch, T | 2 |
| Groenewegen, G | 1 |
| Mathôt, RA | 1 |
| Herben, VM | 1 |
| ten Bokkel Huinink, WW | 1 |
| Swart, M | 1 |
| Ambaum, B | 1 |
| Rosing, H | 1 |
| Jansen, S | 1 |
| Voest, EE | 1 |
| Beijnen, JH | 2 |
| Schellens, JH | 3 |
| Goren, MP | 7 |
| Epelman, S | 2 |
| Bush, DA | 1 |
| Davenport, V | 3 |
| Bessmertny, O | 1 |
| Goldman, SC | 1 |
| Berg, SL | 1 |
| Kreissman, SG | 1 |
| Laver, J | 1 |
| Secola, R | 3 |
| van de Ven, C | 4 |
| Reaman, GH | 4 |
| Angiolillo, AL | 1 |
| Bonilla, MA | 1 |
| Ayello, J | 1 |
| Militano, O | 1 |
| Miller, LL | 1 |
| Krailo, M | 1 |
| Reaman, G | 1 |
| Willits, I | 1 |
| Tilby, MJ | 1 |
| Ford, D | 1 |
| Cholerton, S | 1 |
| Boddy, AV | 3 |
| Sierra, MI | 1 |
| Fernández, A | 1 |
| Blanco, D | 1 |
| Olver, I | 1 |
| Keefe, D | 1 |
| Myers, M | 1 |
| Caruso, D | 1 |
| David, KA | 1 |
| Picus, J | 1 |
| Errington, J | 1 |
| Hale, J | 1 |
| Howe, K | 1 |
| Chisholm, JC | 1 |
| Beane, C | 1 |
| Brennan, B | 1 |
| Waters, F | 1 |
| Glaser, A | 1 |
| Hemsworth, S | 1 |
| McDowell, H | 1 |
| Wright, Y | 1 |
| Pritchard-Jones, K | 1 |
| Pinkerton, R | 1 |
| Jenner, G | 1 |
| Nicholson, J | 1 |
| Elsworth, AM | 1 |
| Sakai, S | 1 |
| Kawabata, K | 1 |
| Tanaka, S | 1 |
| Harimoto, N | 1 |
| Hashimoto, I | 1 |
| Mu, C | 1 |
| Salmons, B | 1 |
| Ijima, H | 1 |
| Kawakami, K | 1 |
| Roy, P | 1 |
| Grill, J | 1 |
| Sabouraud, P | 1 |
| Behar, C | 1 |
| Munzer, M | 1 |
| Motte, J | 1 |
| Hartmann, O | 1 |
| Kilickap, S | 1 |
| Cakar, M | 1 |
| Onal, IK | 1 |
| Tufan, A | 1 |
| Akoglu, H | 1 |
| Aksoy, S | 1 |
| Erman, M | 1 |
| Tekuzman, G | 1 |
| Holzgrabe, U | 1 |
| Garolla, A | 1 |
| Pizzato, C | 1 |
| Ferlin, A | 1 |
| Carli, MO | 1 |
| Selice, R | 1 |
| Foresta, C | 1 |
| Cruz, LB | 1 |
| Ribeiro, AS | 1 |
| Rech, A | 1 |
| Rosa, LG | 1 |
| Castro, CG | 1 |
| Kopf, B | 1 |
| De Giorgi, U | 1 |
| Vertogen, B | 1 |
| Monti, G | 1 |
| Molinari, A | 1 |
| Turci, D | 1 |
| Dazzi, C | 1 |
| Leoni, M | 1 |
| Tienghi, A | 1 |
| Cariello, A | 1 |
| Argnani, M | 1 |
| Frassineti, L | 1 |
| Scarpi, E | 1 |
| Rosti, G | 1 |
| Marangolo, M | 1 |
| Brain, EG | 1 |
| Rezai, K | 1 |
| Weill, S | 1 |
| Gauzan, MF | 1 |
| Santoni, J | 1 |
| Besse, B | 1 |
| Goupil, A | 1 |
| Turpin, F | 1 |
| Urien, S | 1 |
| Lokiec, F | 1 |
| Brüggemann, SK | 1 |
| Pfäffle, S | 1 |
| Peters, SO | 1 |
| Phillips, RS | 1 |
| Tyerman, K | 1 |
| Al-Kassim, MI | 1 |
| Picton, S | 1 |
| Pawlicki, M | 1 |
| Zuchowska-Vogelgesang, B | 1 |
| Holoye, PY | 2 |
| Anderson, T | 2 |
| Duelge, J | 2 |
| Hansen, RM | 2 |
| Ritch, PS | 2 |
| Scheef, W | 4 |
| de Kraker, J | 7 |
| Voûte, PA | 3 |
| Klein, HO | 2 |
| Wickramanayake, PD | 2 |
| Coerper, C | 2 |
| Christian, E | 2 |
| Pohl, J | 2 |
| Brock, N | 5 |
| Burkert, H | 3 |
| Scheulen, ME | 1 |
| Niederle, N | 2 |
| Bremer, K | 2 |
| Schütte, J | 1 |
| Seeber, S | 2 |
| Nobile, MT | 1 |
| Rosso, R | 2 |
| Brema, F | 1 |
| Cinquegrana, A | 1 |
| Santi, L | 1 |
| Retsas, S | 1 |
| Colvin, M | 1 |
| Hunter, HL | 1 |
| Harrison, EF | 1 |
| Czownicki, Z | 1 |
| Utracka-Hutka, B | 1 |
| Falkson, G | 2 |
| Van Dyk, JJ | 1 |
| Stapelberg, R | 1 |
| Falkson, HC | 2 |
| Spitzer, G | 1 |
| Dicke, KA | 1 |
| Litam, J | 1 |
| Verma, DS | 1 |
| Zander, A | 1 |
| Lanzotti, V | 1 |
| Valdivieso, M | 1 |
| McCredie, KB | 2 |
| Samuels, ML | 1 |
| Higi, M | 1 |
| Bierbaum, W | 1 |
| Schmidt, CG | 1 |
| Takahashi, J | 1 |
| Kawashima, R | 1 |
| Abe, Y | 1 |
| Fukuda, H | 1 |
| Kubota, K | 1 |
| Yamada, K | 1 |
| Sato, T | 1 |
| Brugger, W | 6 |
| Henschler, R | 1 |
| Heimfeld, S | 2 |
| Berenson, RJ | 2 |
| Mertelsmann, R | 6 |
| Kanz, L | 8 |
| Elfenbein, GJ | 3 |
| Janssen, WE | 1 |
| Ballester, OF | 2 |
| Hiemenz, JW | 3 |
| Zorsky, PE | 3 |
| Kronish, LE | 2 |
| Foody, MC | 1 |
| Dercksen, MW | 1 |
| Gerritsen, WR | 1 |
| Rodenhuis, S | 1 |
| Dirkson, MK | 1 |
| Slaper-Cortenbach, IC | 1 |
| Schaasberg, WP | 1 |
| Pinedo, HM | 1 |
| von dem Borne, AE | 1 |
| van der Schoot, CE | 1 |
| Toma, S | 1 |
| Palumbo, R | 1 |
| Comandone, A | 2 |
| Oliva, C | 1 |
| Vincenti, M | 1 |
| Bumma, C | 1 |
| González-Manzano, R | 1 |
| Cid, J | 1 |
| Brugarolas, A | 1 |
| Piasecki, CC | 1 |
| Kung, FH | 1 |
| Desai, SJ | 1 |
| Dickerman, JD | 1 |
| Goorin, AM | 1 |
| Harris, MB | 1 |
| Inoue, S | 1 |
| Krischer, JP | 1 |
| Murphy, SB | 1 |
| Pratt, CB | 16 |
| Toledano, S | 1 |
| Chang, AY | 2 |
| Möcklin, W | 1 |
| Birken, R | 1 |
| Bertz, H | 1 |
| Hecht, T | 1 |
| Pressler, K | 2 |
| Frisch, J | 3 |
| Schulz, G | 2 |
| Keizer, HJ | 1 |
| Ouwerkerk, J | 2 |
| Welvaart, K | 1 |
| van der Velde, CJ | 1 |
| Cleton, FJ | 1 |
| van Hoff, J | 1 |
| Grier, HE | 1 |
| Douglass, EC | 5 |
| Green, DM | 1 |
| Jones, DP | 2 |
| Chesney, RW | 1 |
| Katz, A | 1 |
| Anelli, A | 1 |
| Gorender, EF | 1 |
| Cruz, SM | 1 |
| Oliveira, RM | 1 |
| Marques, LA | 1 |
| Anninga, JK | 1 |
| Valdés Olmos, RA | 1 |
| van Tinteren, H | 1 |
| Hoefnagel, CA | 1 |
| van Royen, EA | 1 |
| Elias, AD | 5 |
| Ayash, LJ | 4 |
| Wheeler, C | 4 |
| Schwartz, G | 3 |
| Tepler, I | 1 |
| McCauley, M | 2 |
| Mazanet, R | 1 |
| Schnipper, L | 4 |
| Frei, E | 4 |
| Antman, KH | 3 |
| Rossi, RM | 1 |
| Kist, C | 1 |
| Wurster, U | 1 |
| Külpmann, WR | 1 |
| Ehrich, JH | 3 |
| Prasad, VK | 1 |
| Corlett, SA | 1 |
| Abaasi, K | 1 |
| Heney, D | 1 |
| Lewis, I | 1 |
| Chrystyn, H | 1 |
| DiMaggio, JR | 1 |
| Brown, R | 1 |
| Baile, WF | 1 |
| Schapira, D | 1 |
| Marina, NM | 2 |
| Rodman, JH | 2 |
| Murry, DJ | 1 |
| Shema, SJ | 2 |
| Bowman, LC | 2 |
| Furman, W | 2 |
| Meyer, WH | 10 |
| Lind, MJ | 1 |
| Ardiet, C | 1 |
| Sakuma, H | 1 |
| Matsumoto, E | 1 |
| Kanno, H | 1 |
| Watanabe, M | 1 |
| Kikuta, A | 1 |
| Suzuki, H | 1 |
| Rossi, R | 5 |
| Gödde, A | 1 |
| Kleinebrand, A | 1 |
| Riepenhausen, M | 1 |
| Boos, J | 2 |
| Ritter, J | 1 |
| Jürgens, H | 4 |
| De Schepper, J | 1 |
| Hachimi-Idrissi, S | 1 |
| Verboven, M | 1 |
| Piepsz, A | 1 |
| Otten, J | 1 |
| Wainer, IW | 2 |
| Cameron, JC | 1 |
| Rath, B | 1 |
| Ullrich, K | 1 |
| Hewitt, M | 1 |
| McQuade, B | 1 |
| Stevens, R | 1 |
| Lokich, JJ | 1 |
| Zipoli, TE | 1 |
| Anderson, NR | 1 |
| Moore, C | 1 |
| Gonzalves, L | 1 |
| Bern, MM | 1 |
| Coco, F | 1 |
| Rodman, J | 1 |
| Douglass, E | 2 |
| Hudson, M | 1 |
| Wilimas, J | 3 |
| Meyer, W | 1 |
| Bowman, L | 1 |
| Ochs, J | 1 |
| Marina, N | 4 |
| Avery, L | 2 |
| Thompson, EI | 4 |
| Lokich, J | 1 |
| Skubitz, KM | 1 |
| Boros, L | 1 |
| Garrow, GC | 1 |
| Asbury, RF | 1 |
| Hui, L | 1 |
| Palackdharry, CS | 1 |
| Luo, X | 3 |
| Fang, L | 1 |
| Wiedemann, GJ | 1 |
| Robins, HI | 1 |
| Katschinski, DM | 1 |
| Mentzel, M | 1 |
| van Heek, R | 1 |
| Touhidi, RR | 1 |
| Bucsky, P | 1 |
| Gillis, W | 1 |
| Feyerabend, T | 1 |
| d'Oleire, F | 1 |
| Freund, C | 1 |
| Eleftheriadis, S | 1 |
| Weiss, C | 1 |
| Dueñas-Gonzalez, A | 1 |
| Sobrevilla-Calvo, P | 1 |
| Frias-Mendivil, M | 1 |
| Gallardo-Rincon, D | 1 |
| Lara-Medina, F | 1 |
| Aguilar-Ponce, L | 1 |
| Miranda-Lopez, E | 1 |
| Zinser-Sierra, J | 1 |
| Reynoso-Gomez, E | 1 |
| Lotz, JP | 2 |
| Izrael, V | 1 |
| Womer, RB | 1 |
| Roguin, A | 1 |
| Ben Arush, MW | 1 |
| Higasi, A | 1 |
| Kuten, A | 1 |
| English, MW | 2 |
| Wyllie, RA | 1 |
| Coulthard, MG | 2 |
| Triozzi, PL | 1 |
| Tucker, F | 1 |
| Benzies, T | 1 |
| Balcerzak, SP | 1 |
| Lewis, LD | 5 |
| Fairclough, D | 1 |
| Garrison, L | 3 |
| Bleyer, A | 1 |
| Wyllie, R | 1 |
| Brain, EC | 1 |
| Mita, A | 1 |
| Soulié, P | 1 |
| Errihani, H | 1 |
| Hardy Bessard, AC | 1 |
| Chaouche, M | 1 |
| Delord, JP | 1 |
| Cvitkovic, E | 1 |
| Jasmin, C | 1 |
| Misset, JL | 1 |
| Agaliotis, DP | 1 |
| Mattox, T | 1 |
| Rosen, RM | 1 |
| Liubimova, NV | 1 |
| Kumykova, ZhKh | 1 |
| Kushlinskiĭ, NE | 1 |
| Kasumov, ChM | 1 |
| Durnov, LA | 1 |
| Tonda, ME | 1 |
| Arnold, B | 1 |
| Hanna, R | 1 |
| Bunnell, CA | 1 |
| Thompson, L | 1 |
| Buswell, L | 1 |
| Berkowitz, R | 1 |
| Muto, M | 1 |
| Sheets, E | 1 |
| Shulman, LN | 1 |
| Pronk, LC | 2 |
| de Bruijn, EA | 2 |
| Planting, AS | 3 |
| Locci-Tonelli, D | 2 |
| Groult, V | 2 |
| van Oosterom, AT | 2 |
| MacLean, FR | 1 |
| Hall, AG | 1 |
| English, M | 1 |
| Ibrahim, J | 1 |
| Mills, L | 1 |
| Coleman, N | 1 |
| Warren, D | 1 |
| Teicher, BA | 1 |
| Silies, H | 1 |
| Blaschke, G | 1 |
| Hohenlöchter, B | 1 |
| de Wit, R | 1 |
| Kruit, WH | 1 |
| Lamers, CH | 1 |
| van 't Veer, MB | 1 |
| Luyten, AA | 1 |
| van Beurden, V | 1 |
| Harteveld, M | 1 |
| Schmitz, PI | 1 |
| Stoter, G | 1 |
| Bolhuis, RL | 1 |
| Advani, SH | 1 |
| Vogel, W | 1 |
| Kunert, C | 1 |
| Blumenstengel, K | 1 |
| Fricke, HJ | 1 |
| Kath, R | 2 |
| Sayer, HG | 1 |
| Höffken, K | 2 |
| Kushner, BH | 1 |
| Heller, G | 1 |
| Cheung, NK | 1 |
| Wollner, N | 1 |
| Kramer, K | 1 |
| Bajorin, D | 1 |
| Polyak, T | 1 |
| Meyers, PA | 1 |
| Krailo, MD | 3 |
| Weinthal, JA | 1 |
| Bergeron, S | 2 |
| Blazar, BR | 3 |
| Yule, SM | 1 |
| Foxall, PJ | 1 |
| Singer, JM | 1 |
| Hartley, JM | 1 |
| Neild, GH | 1 |
| Lapsley, M | 1 |
| Nicholson, JK | 1 |
| Souhami, RL | 1 |
| Mulders, TM | 1 |
| van der Velde, EA | 1 |
| Breimer, DD | 1 |
| Mulder, GJ | 1 |
| Pleyer, J | 1 |
| Schäfers, P | 1 |
| Kuhn, N | 1 |
| Kleta, R | 1 |
| Deufel, T | 1 |
| Cesana, C | 1 |
| Regazzi, E | 1 |
| Garau, D | 1 |
| Caramatti, C | 1 |
| Mangoni, L | 1 |
| Rizzoli, V | 1 |
| Pelgrims, J | 1 |
| De Vos, F | 1 |
| Prové, A | 1 |
| Kosmas, C | 1 |
| Tsavaris, NB | 1 |
| Polyzos, A | 1 |
| Malamos, NA | 1 |
| Katsikas, M | 1 |
| Antonopoulos, MJ | 1 |
| Ando, Y | 1 |
| Moyano, AJ | 1 |
| Seguí, MA | 1 |
| Abad, T | 1 |
| Urruticoechea, L | 1 |
| García López, JL | 1 |
| Nogué, M | 1 |
| Dominguez, MS | 1 |
| Balcells, M | 1 |
| Dorado, JF | 1 |
| De Pas, T | 1 |
| Curigliano, G | 1 |
| Catania, C | 1 |
| de Braud, F | 1 |
| Knop, S | 2 |
| Fels, LM | 2 |
| van Vangerow, A | 1 |
| Stolte, H | 1 |
| Creaven, PJ | 3 |
| Meropol, NJ | 1 |
| Bolanowska-Higdon, W | 1 |
| Zdanowicz, J | 1 |
| Murphy, M | 1 |
| Payne, GS | 1 |
| Pinkerton, CR | 3 |
| Bouffet, E | 1 |
| Leach, MO | 1 |
| Di Marco, MP | 1 |
| Granvil, CL | 1 |
| Batist, G | 1 |
| Ducharme, MP | 1 |
| Stolt, H | 1 |
| Briasoulis, E | 1 |
| Judson, I | 1 |
| Pavlidis, N | 1 |
| Beale, P | 1 |
| Wanders, J | 1 |
| Groot, Y | 1 |
| Veerman, G | 1 |
| Schuessler, M | 1 |
| Niebch, G | 1 |
| Siamopoulos, K | 1 |
| Tzamakou, E | 1 |
| Rammou, D | 1 |
| Wolf, L | 1 |
| Walker, R | 1 |
| Hanauske, A | 1 |
| Bauer, M | 1 |
| Miser, JS | 2 |
| Sato, JK | 1 |
| Blatt, J | 1 |
| Frierdich, S | 1 |
| Liu-Mares, W | 2 |
| Bracho, F | 1 |
| Panoskaltsis-Mortari, A | 1 |
| Ames, MM | 1 |
| Reid, JM | 1 |
| Miglietta, L | 1 |
| Marenghi, C | 1 |
| Nizzo, R | 1 |
| Foglia, G | 1 |
| Ragni, N | 1 |
| Boccardo, F | 1 |
| Thall, PF | 1 |
| Cheng, SC | 1 |
| Mathĵt, RA | 1 |
| Fouladi, M | 1 |
| Stempak, D | 1 |
| Gammon, J | 1 |
| Klein, J | 1 |
| Grant, R | 1 |
| Greenberg, ML | 1 |
| Baruchel, S | 1 |
| Lee, BS | 1 |
| Lee, JH | 2 |
| Kang, HG | 1 |
| Hahn, H | 1 |
| Shin, HY | 1 |
| Ha, IS | 1 |
| Cheong, HI | 1 |
| Ahn, HS | 1 |
| Choi, Y | 1 |
| Caglar, M | 1 |
| Yarís, N | 1 |
| Akyuz, C | 1 |
| Christodoulou, C | 1 |
| Klouvas, G | 1 |
| Efstathiou, E | 1 |
| Zervakis, D | 1 |
| Papazachariou, E | 1 |
| Plyta, M | 1 |
| Skarlos, DV | 1 |
| Nielsen, E | 1 |
| Brant, J | 1 |
| Dittrich, C | 1 |
| Chen, L | 1 |
| Schneider, CP | 1 |
| Merkel, U | 1 |
| Grübner, U | 1 |
| Hoffmann, A | 1 |
| Graziano, F | 1 |
| Bisonni, R | 1 |
| Catalano, V | 1 |
| Silva, R | 1 |
| Rovidati, S | 1 |
| Mencarini, E | 1 |
| Ferraro, B | 1 |
| Canestrari, F | 1 |
| Baldelli, AM | 1 |
| De Gaetano, A | 1 |
| Giordani, P | 1 |
| Testa, E | 1 |
| Lai, V | 1 |
| Brühl, P | 2 |
| Hoefer-Janker, H | 3 |
| Vahlensieck, W | 2 |
| Carter, SK | 2 |
| Slavik, M | 2 |
| Ritter, S | 1 |
| Schröder, HJ | 1 |
| Costanzi, JJ | 1 |
| Hartwich, G | 1 |
| Neidhardt, B | 1 |
| Lutz, H | 1 |
| Wicart, L | 1 |
| Nelson, RL | 2 |
| Cohen, MH | 1 |
| Fossieck, BE | 1 |
| Günther, U | 2 |
| Hüls, W | 2 |
| Schnitker, J | 1 |
| Fichtner, E | 1 |
| Przybylski, M | 1 |
| Ringsdorf, H | 1 |
| Lenssen, U | 1 |
| Peter, G | 1 |
| Voelcker, G | 1 |
| Hohorst, HJ | 1 |
| Madej, G | 1 |
| Zelechowska, JA | 1 |
| Clavel, B | 1 |
| Mathé, G | 1 |
| Hayat, M | 1 |
| Allen, LM | 1 |
| Rodriguez, V | 1 |
| Bodey, GP | 1 |
| Freireich, EJ | 1 |
| McKelvey, EM | 1 |
| Tashima, CK | 1 |
| Bross, K | 1 |
| Dern, P | 1 |
| Weber, B | 1 |
| Weiss, RB | 2 |
| Wilson, WH | 1 |
| Jain, V | 1 |
| Bryant, G | 1 |
| Cowan, KH | 1 |
| Carter, C | 1 |
| Cottler-Fox, M | 1 |
| Goldspiel, B | 1 |
| Steinberg, SM | 1 |
| Longo, DL | 1 |
| Wittes, RE | 1 |
| Burton, LC | 1 |
| Harper, PG | 3 |
| Rogers, HJ | 4 |
| Merimsky, O | 1 |
| Reider-Groswasser, I | 1 |
| Wigler, N | 1 |
| Chaitchik, S | 1 |
| Schmoll, HJ | 1 |
| Harstrick, A | 1 |
| Illiger, HJ | 1 |
| Metzner, B | 1 |
| Ruther, U | 1 |
| Osternamm, A | 1 |
| Preiss, J | 1 |
| Wilke, H | 1 |
| Hohnloser, J | 1 |
| Shore, R | 1 |
| Greenberg, M | 1 |
| Geary, D | 1 |
| Uhlenbusch, R | 1 |
| Dechant, KL | 1 |
| Brogden, RN | 1 |
| Pilkington, T | 1 |
| Faulds, D | 1 |
| Loeffler, TM | 1 |
| Weber, FW | 1 |
| Hausamen, TU | 1 |
| Cerny, T | 2 |
| Graf, A | 1 |
| Rohner, P | 1 |
| Zeugin, T | 1 |
| Brunner, KW | 1 |
| Küpfer, A | 2 |
| Kurowski, V | 1 |
| Eder, JP | 3 |
| Deary, J | 2 |
| Weissman, L | 2 |
| Hunt, M | 2 |
| Critchlow, J | 2 |
| Vogelzang, NJ | 1 |
| Schryber, S | 1 |
| Dorr, RT | 1 |
| Machover, D | 1 |
| Malassagne, B | 1 |
| Hingh, B | 1 |
| Donsimoni, R | 1 |
| Gumus, Y | 1 |
| Gerota, J | 1 |
| Lam, Y | 1 |
| Tulliez, M | 1 |
| Marsiglia, H | 1 |
| Shaw, PJ | 1 |
| Eden, T | 1 |
| Fitzgerald, DL | 2 |
| Mohan, P | 1 |
| Thatcher, N | 1 |
| Shea, T | 1 |
| Begg, CB | 1 |
| Schoenike, SE | 1 |
| Dana, WJ | 1 |
| Perevodchikova, NI | 1 |
| Orel, NF | 1 |
| Trofimova, NV | 1 |
| Schneider, B | 1 |
| Singh, B | 1 |
| Dodge, RK | 3 |
| Etcubanas, E | 3 |
| Green, AA | 4 |
| Hayes, FA | 4 |
| Horowitz, ME | 5 |
| Wilimas, JA | 3 |
| Ninane, J | 1 |
| Baurain, R | 1 |
| Ferster, A | 1 |
| Trouet, A | 1 |
| Cornu, G | 1 |
| Etcubanas, EL | 1 |
| Davies, SM | 1 |
| Falkson, CI | 1 |
| Wright, RK | 2 |
| Viar, MJ | 2 |
| Treuner, J | 1 |
| Winkler, K | 1 |
| Göbel, U | 1 |
| Pritchard, J | 2 |
| Kandylis, K | 1 |
| Vassilomanolakis, M | 1 |
| Tsoussis, S | 1 |
| Efremidis, AP | 1 |
| Thompson, E | 1 |
| Igarashi, M | 1 |
| Andriole, GL | 1 |
| Sandlund, JT | 1 |
| Arasi, V | 1 |
| Linehan, M | 1 |
| Magrath, IT | 1 |
| Li, GC | 2 |
| Li, JQ | 2 |
| Guan, ZZ | 2 |
| He, YJ | 2 |
| Philip, PA | 1 |
| James, CA | 1 |
| Lazarus, HM | 1 |
| Berger, NA | 1 |
| Cavalli, F | 1 |
| Muchi, H | 1 |
| Taniguchi, Y | 1 |
| Makino, S | 1 |
| Kovnar, EH | 1 |
| Brade, WP | 1 |
| Herdrich, K | 1 |
| Varini, M | 1 |
| Rogers, H | 1 |
| James, C | 1 |
| Bowman, A | 1 |
| Barbor, PR | 1 |
| Eden, OB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Dose of Escalation Design to Investigate the Therapeutic Role of RNA Fragments in the Protection of Platelet Production During Chemotherapy[NCT01163110] | Phase 1 | 32 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| A Phase I Study of Thrombopoietin (rhTPO) Plus G-CSF in Children Receiving Ifosfamide, Carboplatin, and Etoposide (I.C.E.) Chemotherapy for Recurrent or Refractory Solid Tumors[NCT00003597] | Phase 1 | 16 participants (Actual) | Interventional | 1998-11-30 | Completed | ||
| Laser Therapy Associated With Photodynamic Therapy in the Treatment of Oral Mucositis Induced by Chemotherapy in Young Patients: Randomized Blind Clinical Trial[NCT02555501] | Phase 3 | 18 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525] | Phase 3 | 59 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
48 reviews available for ifosfamide and Neoplasms
| Article | Year |
|---|---|
Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance.
Topics: Antineoplastic Agents; Carboplatin; Child; Cisplatin; Humans; Ifosfamide; Kidney; Kidney Diseases; N | 2018 |
Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance.
Topics: Antineoplastic Agents; Carboplatin; Child; Cisplatin; Humans; Ifosfamide; Kidney; Kidney Diseases; N | 2018 |
Renal toxicity and chemotherapy in children with cancer.
Topics: Age of Onset; Antineoplastic Agents; Child; Child, Preschool; Cisplatin; Humans; Ifosfamide; Inciden | 2017 |
Renal toxicity and chemotherapy in children with cancer.
Topics: Age of Onset; Antineoplastic Agents; Child; Child, Preschool; Cisplatin; Humans; Ifosfamide; Inciden | 2017 |
[Classical oxazaphosphorines--metabolism and therapeutic properties--new implications].
Topics: Acetaldehyde; Aldehyde Dehydrogenase; Animals; Antineoplastic Agents; Biotransformation; Cyclophosph | 2013 |
[Classical oxazaphosphorines--metabolism and therapeutic properties--new implications].
Topics: Acetaldehyde; Aldehyde Dehydrogenase; Animals; Antineoplastic Agents; Biotransformation; Cyclophosph | 2013 |
[An overview of glycoconjugates for cancer targeting therapy and diagnosis].
Topics: Animals; Antineoplastic Agents; Drug Carriers; Energy Metabolism; Glucose; Glycoconjugates; Glycolys | 2013 |
[An overview of glycoconjugates for cancer targeting therapy and diagnosis].
Topics: Animals; Antineoplastic Agents; Drug Carriers; Energy Metabolism; Glucose; Glycoconjugates; Glycolys | 2013 |
Oxazaphosphorines: new therapeutic strategies for an old class of drugs.
Topics: Animals; Antineoplastic Agents, Alkylating; Cyclophosphamide; Cytochrome P-450 Enzyme System; Drug D | 2010 |
Oxazaphosphorines: new therapeutic strategies for an old class of drugs.
Topics: Animals; Antineoplastic Agents, Alkylating; Cyclophosphamide; Cytochrome P-450 Enzyme System; Drug D | 2010 |
Glufosfamide as a new oxazaphosphorine anticancer agent.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell | 2011 |
Glufosfamide as a new oxazaphosphorine anticancer agent.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell | 2011 |
Glufosfamide: can we improve the process of anticancer agent development?
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Drug Discovery; Glucose; Humans; Ifosfamide; Neop | 2012 |
Glufosfamide: can we improve the process of anticancer agent development?
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Drug Discovery; Glucose; Humans; Ifosfamide; Neop | 2012 |
Glufosfamide (Baxter Oncology).
Topics: Animals; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Glucose; Humans; Ifosfamide; N | 2002 |
Glufosfamide (Baxter Oncology).
Topics: Animals; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Glucose; Humans; Ifosfamide; N | 2002 |
New chemotherapy agents in veterinary medicine.
Topics: Animals; Antineoplastic Agents; Cat Diseases; Cats; Deoxycytidine; Dog Diseases; Dogs; Gemcitabine; | 2003 |
New chemotherapy agents in veterinary medicine.
Topics: Animals; Antineoplastic Agents; Cat Diseases; Cats; Deoxycytidine; Dog Diseases; Dogs; Gemcitabine; | 2003 |
Chronic ifosfamide nephrotoxicity in children.
Topics: Antineoplastic Agents, Alkylating; Child; Chronic Disease; Humans; Ifosfamide; Kidney Diseases; Neop | 2003 |
Chronic ifosfamide nephrotoxicity in children.
Topics: Antineoplastic Agents, Alkylating; Child; Chronic Disease; Humans; Ifosfamide; Kidney Diseases; Neop | 2003 |
Ifosfamide in pediatric solid tumors.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Germinoma; Humans; Ifosf | 2003 |
Ifosfamide in pediatric solid tumors.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Germinoma; Humans; Ifosf | 2003 |
Glufosfamide: beta-D-Glc-IPM, D 19575.
Topics: Antineoplastic Agents, Alkylating; Breast Neoplasms; Clinical Trials as Topic; Female; Glucose; Huma | 2005 |
Glufosfamide: beta-D-Glc-IPM, D 19575.
Topics: Antineoplastic Agents, Alkylating; Breast Neoplasms; Clinical Trials as Topic; Female; Glucose; Huma | 2005 |
Evaluating risk factors for the development of ifosfamide encephalopathy.
Topics: Adult; Aged; Akathisia, Drug-Induced; Antineoplastic Agents, Alkylating; Brain Diseases; Cohort Stud | 2005 |
Evaluating risk factors for the development of ifosfamide encephalopathy.
Topics: Adult; Aged; Akathisia, Drug-Induced; Antineoplastic Agents, Alkylating; Brain Diseases; Cohort Stud | 2005 |
Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Cyclophosphamide; Cytochrome P-450 Enzyme System; Geneti | 2006 |
Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Cyclophosphamide; Cytochrome P-450 Enzyme System; Geneti | 2006 |
A systematic review of the accuracy and utility of early markers of Ifosfamide-induced proximal tubulopathy in survivors of childhood cancers.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents, Alkylating; Biomarkers; Child; Child, Presc | 2008 |
A systematic review of the accuracy and utility of early markers of Ifosfamide-induced proximal tubulopathy in survivors of childhood cancers.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents, Alkylating; Biomarkers; Child; Child, Presc | 2008 |
[New antineoplastic agents, their value and use].
Topics: Aminacrine; Antineoplastic Agents; Aspartic Acid; Cisplatin; Etoposide; Humans; Ifosfamide; Interfer | 1982 |
[New antineoplastic agents, their value and use].
Topics: Aminacrine; Antineoplastic Agents; Aspartic Acid; Cisplatin; Etoposide; Humans; Ifosfamide; Interfer | 1982 |
The comparative pharmacology of cyclophosphamide and ifosfamide.
Topics: Alkylation; Biotransformation; Chemical Phenomena; Chemistry; Cyclophosphamide; Half-Life; Humans; I | 1982 |
The comparative pharmacology of cyclophosphamide and ifosfamide.
Topics: Alkylation; Biotransformation; Chemical Phenomena; Chemistry; Cyclophosphamide; Half-Life; Humans; I | 1982 |
Ifosfamide: European perspective.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administrat | 1982 |
Ifosfamide: European perspective.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administrat | 1982 |
The anticancer spectrum of ifosfamide.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Lung Neoplasms; Mal | 1982 |
The anticancer spectrum of ifosfamide.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Lung Neoplasms; Mal | 1982 |
Strategies to prevent nephrotoxicity of anticancer drugs.
Topics: Adult; Antineoplastic Agents; Cell Line; Chelating Agents; Child; Child, Preschool; Cisplatin; Human | 1995 |
Strategies to prevent nephrotoxicity of anticancer drugs.
Topics: Adult; Antineoplastic Agents; Cell Line; Chelating Agents; Child; Child, Preschool; Cisplatin; Human | 1995 |
The use of ifosfamide, carboplatin, and etoposide in children with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Etoposide; Humans; Ifosfamide; L | 1995 |
The use of ifosfamide, carboplatin, and etoposide in children with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Etoposide; Humans; Ifosfamide; L | 1995 |
Renal toxicity of cancer chemotherapeutic agents in children: ifosfamide and cisplatin.
Topics: Child; Cisplatin; Glomerular Filtration Rate; Humans; Ifosfamide; Kidney; Kidney Diseases; Kidney Tu | 1995 |
Renal toxicity of cancer chemotherapeutic agents in children: ifosfamide and cisplatin.
Topics: Child; Cisplatin; Glomerular Filtration Rate; Humans; Ifosfamide; Kidney; Kidney Diseases; Kidney Tu | 1995 |
Pharmacokinetics of alkylating agents.
Topics: Alkylating Agents; Carmustine; Chlorambucil; Cyclophosphamide; Humans; Ifosfamide; Lomustine; Melpha | 1993 |
Pharmacokinetics of alkylating agents.
Topics: Alkylating Agents; Carmustine; Chlorambucil; Cyclophosphamide; Humans; Ifosfamide; Lomustine; Melpha | 1993 |
Haematopoietic growth factors and peripheral blood stem cells as supportive agents in dose intensification.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion, Autologous; Cis | 1993 |
Haematopoietic growth factors and peripheral blood stem cells as supportive agents in dose intensification.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion, Autologous; Cis | 1993 |
Stereoisomers in clinical oncology: why it is important to know what the right and left hands are doing.
Topics: Antineoplastic Agents; Humans; Ifosfamide; Leucovorin; Neoplasms; Stereoisomerism; Verapamil | 1993 |
Stereoisomers in clinical oncology: why it is important to know what the right and left hands are doing.
Topics: Antineoplastic Agents; Humans; Ifosfamide; Leucovorin; Neoplasms; Stereoisomerism; Verapamil | 1993 |
Ongoing clinical studies of ifosfamide for pediatric cancer in the United States.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 1996 |
Ongoing clinical studies of ifosfamide for pediatric cancer in the United States.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 1996 |
[Clinical studies on combination of ifosfamide, carboplatin and etoposide (ICE) with whole body hyperthermia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; H | 1996 |
[Clinical studies on combination of ifosfamide, carboplatin and etoposide (ICE) with whole body hyperthermia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; H | 1996 |
The role of ifosfamide in paediatric cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Child; Humans; If | 1998 |
The role of ifosfamide in paediatric cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Child; Humans; If | 1998 |
Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Dose-Response Relationsh | 2000 |
Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Dose-Response Relationsh | 2000 |
Ifosfamide in the elderly: clinical considerations for a better drug management.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Humans; Ifosfamide; Neoplas | 2000 |
Ifosfamide in the elderly: clinical considerations for a better drug management.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Humans; Ifosfamide; Neoplas | 2000 |
Chemotherapy-induced neurotoxicity: assessment and interventions for patients at risk.
Topics: Antineoplastic Agents; Cisplatin; Cytarabine; Humans; Ifosfamide; Methotrexate; Neoplasms; Neurotoxi | 2002 |
Chemotherapy-induced neurotoxicity: assessment and interventions for patients at risk.
Topics: Antineoplastic Agents; Cisplatin; Cytarabine; Humans; Ifosfamide; Methotrexate; Neoplasms; Neurotoxi | 2002 |
Introducing ifosfamide in innovative treatment modalities.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Child; Drug Delivery Systems; Humans; Ifosfamid | 2002 |
Introducing ifosfamide in innovative treatment modalities.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Child; Drug Delivery Systems; Humans; Ifosfamid | 2002 |
Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer.
Topics: Antineoplastic Agents, Alkylating; Bystander Effect; Cyclophosphamide; Cytochrome P-450 Enzyme Syste | 2002 |
Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer.
Topics: Antineoplastic Agents, Alkylating; Bystander Effect; Cyclophosphamide; Cytochrome P-450 Enzyme Syste | 2002 |
Investigational drugs under study by the United States National Cancer Institute.
Topics: Acrylates; Alkylating Agents; Ancitabine; Animals; Antibiotics, Antineoplastic; Antimetabolites, Ant | 1976 |
Investigational drugs under study by the United States National Cancer Institute.
Topics: Acrylates; Alkylating Agents; Ancitabine; Animals; Antibiotics, Antineoplastic; Antimetabolites, Ant | 1976 |
Current investigational drugs of interest in the Chemotherapy Program of the National Cancer Institute.
Topics: Altretamine; Animals; Antineoplastic Agents; Asparaginase; Azacitidine; Bleomycin; Cisplatin; Dacarb | 1977 |
Current investigational drugs of interest in the Chemotherapy Program of the National Cancer Institute.
Topics: Altretamine; Animals; Antineoplastic Agents; Asparaginase; Azacitidine; Bleomycin; Cisplatin; Dacarb | 1977 |
Hypersensitivity reactions.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Aziridines; Benzoquinones; Bleomyc | 1992 |
Hypersensitivity reactions.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Aziridines; Benzoquinones; Bleomyc | 1992 |
Ifosfamide in pediatric oncology.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Protoc | 1992 |
Ifosfamide in pediatric oncology.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Protoc | 1992 |
Current studies of ifosfamide for pediatric solid tumors and leukemia in the United States.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Chil | 1992 |
Current studies of ifosfamide for pediatric solid tumors and leukemia in the United States.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Chil | 1992 |
Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.
Topics: Drug Evaluation; Drug Therapy, Combination; Female; Humans; Ifosfamide; Male; Mesna; Neoplasms | 1991 |
Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.
Topics: Drug Evaluation; Drug Therapy, Combination; Female; Humans; Ifosfamide; Male; Mesna; Neoplasms | 1991 |
Ifosfamide in pediatric oncology.
Topics: Child; Child, Preschool; Humans; Ifosfamide; Infant; Neoplasms | 1991 |
Ifosfamide in pediatric oncology.
Topics: Child; Child, Preschool; Humans; Ifosfamide; Infant; Neoplasms | 1991 |
Nephrotoxicity from chemotherapy: prevention and management.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Gallium; Humans; Ifosfamide; Kidney Diseases; Methotr | 1991 |
Nephrotoxicity from chemotherapy: prevention and management.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Gallium; Humans; Ifosfamide; Kidney Diseases; Methotr | 1991 |
Chemoprotectants for cancer chemotherapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Cisplatin; Cyclophosphamide; Fluor | 1991 |
Chemoprotectants for cancer chemotherapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Cisplatin; Cyclophosphamide; Fluor | 1991 |
Ifosfamide in paediatric oncology: tried but not tested?
Topics: Child; Cyclophosphamide; Evaluation Studies as Topic; Humans; Ifosfamide; Neoplasms; Prognosis; Sarc | 1990 |
Ifosfamide in paediatric oncology: tried but not tested?
Topics: Child; Cyclophosphamide; Evaluation Studies as Topic; Humans; Ifosfamide; Neoplasms; Prognosis; Sarc | 1990 |
Ifosfamide and mesna.
Topics: Animals; Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms | 1990 |
Ifosfamide and mesna.
Topics: Animals; Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms | 1990 |
Ifosfamide studies for primary or recurrent pediatric malignant solid tumors and leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Ifosfamide; Leukemia; Lymphoma; Neopl | 1990 |
Ifosfamide studies for primary or recurrent pediatric malignant solid tumors and leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Ifosfamide; Leukemia; Lymphoma; Neopl | 1990 |
Ifosfamide in pediatric malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Ifosfamide; Neoplasms | 1989 |
Ifosfamide in pediatric malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Ifosfamide; Neoplasms | 1989 |
Chemotherapy of malignant disease: an update.
Topics: Amsacrine; Antineoplastic Agents; Cisplatin; Coformycin; Etoposide; Female; Humans; Ifosfamide; Male | 1988 |
Chemotherapy of malignant disease: an update.
Topics: Amsacrine; Antineoplastic Agents; Cisplatin; Coformycin; Etoposide; Female; Humans; Ifosfamide; Male | 1988 |
Ifosfamide--pharmacology, safety and therapeutic potential.
Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu | 1985 |
Ifosfamide--pharmacology, safety and therapeutic potential.
Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu | 1985 |
96 trials available for ifosfamide and Neoplasms
| Article | Year |
|---|---|
Analysis of the clinical characteristics of pediatric patients who experience ifosfamide-induced encephalopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Child; Child, Preschool | 2019 |
Analysis of the clinical characteristics of pediatric patients who experience ifosfamide-induced encephalopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Child; Child, Preschool | 2019 |
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
Topics: Adolescent; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Central Nervous | 2021 |
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
Topics: Adolescent; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Central Nervous | 2021 |
Urine biomarkers of acute kidney injury in noncritically ill, hospitalized children treated with chemotherapy.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Child; | 2017 |
Urine biomarkers of acute kidney injury in noncritically ill, hospitalized children treated with chemotherapy.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Child; | 2017 |
A non-comparative phase II study of dose intensive chemotherapy with doxorubicin and ifosfamide followed by high dose ICE consolidation with PBSCT in non-resectable, high grade, adult type soft tissue sarcomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Etoposide; Female; | 2013 |
A non-comparative phase II study of dose intensive chemotherapy with doxorubicin and ifosfamide followed by high dose ICE consolidation with PBSCT in non-resectable, high grade, adult type soft tissue sarcomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Etoposide; Female; | 2013 |
Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, | 2014 |
Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, | 2014 |
Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazin | 2014 |
Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazin | 2014 |
Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Etoposid | 2015 |
Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Etoposid | 2015 |
An original administration of ifosfamide given once every other week: a clinical and pharmacological study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Chromatography, Gas; Cytochrome P- | 2008 |
An original administration of ifosfamide given once every other week: a clinical and pharmacological study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Chromatography, Gas; Cytochrome P- | 2008 |
Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dose-Response R | 2009 |
Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dose-Response R | 2009 |
Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Female; Glucose; Humans; Ifosfamide; Infusions, Intravenous; Male; Midd | 2010 |
Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Female; Glucose; Humans; Ifosfamide; Infusions, Intravenous; Male; Midd | 2010 |
Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Brain Injuries; | 2010 |
Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Brain Injuries; | 2010 |
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Inte | 2010 |
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Inte | 2010 |
Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia.
Topics: Adult; Aged; Antineoplastic Agents; Blood Platelets; Dacarbazine; Dose-Response Relationship, Drug; | 2010 |
Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia.
Topics: Adult; Aged; Antineoplastic Agents; Blood Platelets; Dacarbazine; Dose-Response Relationship, Drug; | 2010 |
Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Combined Modality Therapy; | 2011 |
Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Combined Modality Therapy; | 2011 |
Phase I study of docetaxel plus ifosfamide in patients with advanced cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Respons | 2002 |
Phase I study of docetaxel plus ifosfamide in patients with advanced cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Respons | 2002 |
Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Carboplatin; Chromatography, High Pressure Liqu | 2003 |
Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Carboplatin; Chromatography, High Pressure Liqu | 2003 |
Two schedules of application for mesna and their influence on the thiol-metabolism.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubicin; Etoposide; | 2003 |
Two schedules of application for mesna and their influence on the thiol-metabolism.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubicin; Etoposide; | 2003 |
Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carboplatin; Child; Child, Presc | 2004 |
Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carboplatin; Child; Child, Presc | 2004 |
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; D | 2004 |
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; D | 2004 |
Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Female | 2004 |
Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Female | 2004 |
Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch | 2005 |
Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch | 2005 |
A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Gro
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Child; Ch | 2005 |
A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Gro
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Child; Ch | 2005 |
A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Agents, Alkylating; Cohort Studie | 2005 |
A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Agents, Alkylating; Cohort Studie | 2005 |
Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study.
Topics: Adolescent; Adult; Analysis of Variance; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylat | 2005 |
Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study.
Topics: Adolescent; Adult; Analysis of Variance; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylat | 2005 |
Influence of low-energy laser in the prevention of oral mucositis in children with cancer receiving chemotherapy.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Campt | 2007 |
Influence of low-energy laser in the prevention of oral mucositis in children with cancer receiving chemotherapy.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Campt | 2007 |
A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemothera | 2006 |
A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemothera | 2006 |
Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study.
Topics: Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Cross-Over Studies; Drug Administration | 2007 |
Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study.
Topics: Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Cross-Over Studies; Drug Administration | 2007 |
Influence of short-term use of dexamethasone on the pharmacokinetics of ifosfamide in patients.
Topics: Acetaldehyde; Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Dexamethasone | 2007 |
Influence of short-term use of dexamethasone on the pharmacokinetics of ifosfamide in patients.
Topics: Acetaldehyde; Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Dexamethasone | 2007 |
Use and safety of high-dose ifosfamide.
Topics: Adenocarcinoma; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cyc | 1982 |
Use and safety of high-dose ifosfamide.
Topics: Adenocarcinoma; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cyc | 1982 |
Clinical overview of mesna.
Topics: Clinical Trials as Topic; Cyclophosphamide; Drug Interactions; Hematuria; Humans; Ifosfamide; Mercap | 1983 |
Clinical overview of mesna.
Topics: Clinical Trials as Topic; Cyclophosphamide; Drug Interactions; Hematuria; Humans; Ifosfamide; Mercap | 1983 |
Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557).
Topics: Animals; Clinical Trials as Topic; Cyclophosphamide; Humans; Ifosfamide; Infusions, Parenteral; Kidn | 1984 |
Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557).
Topics: Animals; Clinical Trials as Topic; Cyclophosphamide; Humans; Ifosfamide; Infusions, Parenteral; Kidn | 1984 |
Phase II study of ifosfamide combined with Mesna uroprotection in advanced non-small-cell lung carcinoma and other solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Humans; Ifosfa | 1984 |
Phase II study of ifosfamide combined with Mesna uroprotection in advanced non-small-cell lung carcinoma and other solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Humans; Ifosfa | 1984 |
Ifosfamide: European perspective.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administrat | 1982 |
Ifosfamide: European perspective.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administrat | 1982 |
[Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
Topics: Clinical Trials as Topic; Cyclophosphamide; Cystitis; Hematuria; Humans; Ifosfamide; Mercaptoethanol | 1981 |
[Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
Topics: Clinical Trials as Topic; Cyclophosphamide; Cystitis; Hematuria; Humans; Ifosfamide; Mercaptoethanol | 1981 |
Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Ble | 1994 |
Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Ble | 1994 |
High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relati | 1994 |
High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relati | 1994 |
Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study.
Topics: Adult; Aged; Ambulatory Care; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Imm | 1995 |
Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study.
Topics: Adult; Aged; Ambulatory Care; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Imm | 1995 |
Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 1995 |
Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 1995 |
Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch | 1995 |
Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch | 1995 |
Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors. Response and toxicity.
Topics: Adolescent; Adult; Bone Marrow; Child; Child, Preschool; Cisplatin; Drug Administration Schedule; Dr | 1995 |
Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors. Response and toxicity.
Topics: Adolescent; Adult; Bone Marrow; Child; Child, Preschool; Cisplatin; Drug Administration Schedule; Dr | 1995 |
A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Fe | 1995 |
A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Fe | 1995 |
High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Forecasting; Hematolo | 1994 |
High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Forecasting; Hematolo | 1994 |
Ifosfamide, carboplatin, and etoposide: a new regimen with a broad spectrum of activity.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; H | 1994 |
Ifosfamide, carboplatin, and etoposide: a new regimen with a broad spectrum of activity.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; H | 1994 |
Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Child; Child, Pre | 1994 |
Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Child; Child, Pre | 1994 |
[Ifosfamide-induced nephrotoxicity].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Cisplatin; Creatinine | 1993 |
[Ifosfamide-induced nephrotoxicity].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Cisplatin; Creatinine | 1993 |
The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children.
Topics: Antineoplastic Agents; Child; Cisplatin; Female; Humans; Ifosfamide; Male; Nausea; Neoplasms; Ondans | 1993 |
The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children.
Topics: Antineoplastic Agents; Child; Cisplatin; Female; Humans; Ifosfamide; Male; Nausea; Neoplasms; Ondans | 1993 |
Pilot study of ambulatory infusional ifosfamide admixed with carboplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Ifosfamide; Infusions, Intraven | 1993 |
Pilot study of ambulatory infusional ifosfamide admixed with carboplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Ifosfamide; Infusions, Intraven | 1993 |
Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch | 1993 |
Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch | 1993 |
A phase I study of ifosfamide with Mesna given daily for 3 consecutive days to children with malignant solid tumors.
Topics: Adolescent; Adult; Carboplatin; Child; Child, Preschool; Cisplatin; Drug Administration Schedule; Fe | 1993 |
A phase I study of ifosfamide with Mesna given daily for 3 consecutive days to children with malignant solid tumors.
Topics: Adolescent; Adult; Carboplatin; Child; Child, Preschool; Cisplatin; Drug Administration Schedule; Fe | 1993 |
Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Antineoplastic Combined Chemotherapy Proto | 1996 |
Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Antineoplastic Combined Chemotherapy Proto | 1996 |
Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytog | 1996 |
Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytog | 1996 |
Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: a single hospital experience.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chil | 1996 |
Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: a single hospital experience.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chil | 1996 |
Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 1996 |
Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Antineoplastic Combined Chemotherapy Protocols; Carbopla | 1996 |
Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etopo | 1995 |
Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etopo | 1995 |
Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor.
Topics: Adult; Aged; Antigen-Presenting Cells; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; | 1996 |
Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor.
Topics: Adult; Aged; Antigen-Presenting Cells; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; | 1996 |
A study of 5 day fractionated ifosfamide pharmacokinetics in consecutive treatment cycles.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Female; Half-Life; Humans; Ifosfam | 1996 |
A study of 5 day fractionated ifosfamide pharmacokinetics in consecutive treatment cycles.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Female; Half-Life; Humans; Ifosfam | 1996 |
Phase I trial of subcutaneous interleukin-1 alpha in children with malignant solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Bone Marrow; Bon | 1997 |
Phase I trial of subcutaneous interleukin-1 alpha in children with malignant solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Bone Marrow; Bon | 1997 |
Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplati | 1998 |
Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplati | 1998 |
A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Fe | 1998 |
A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Fe | 1998 |
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female; | 1998 |
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female; | 1998 |
Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female; | 1998 |
Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female; | 1998 |
Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Hypoxia; Disease-Free Survi | 1998 |
Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Hypoxia; Disease-Free Survi | 1998 |
A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, | 1998 |
A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, | 1998 |
Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carmustine; | 1998 |
Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carmustine; | 1998 |
High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dose-Res | 1998 |
High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dose-Res | 1998 |
A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer G
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Car | 1998 |
A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer G
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Car | 1998 |
Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, | 2000 |
Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, | 2000 |
Ifosfamide and irinotecan in solid tumors: a phase I dose-finding trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Ifosfamid | 2000 |
Ifosfamide and irinotecan in solid tumors: a phase I dose-finding trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Ifosfamid | 2000 |
The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Ifosfa | 2000 |
The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Ifosfa | 2000 |
Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione.
Topics: Acetaldehyde; Antineoplastic Agents, Alkylating; Cysteine; Dose-Response Relationship, Drug; Glutath | 2000 |
Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione.
Topics: Acetaldehyde; Antineoplastic Agents, Alkylating; Cysteine; Dose-Response Relationship, Drug; Glutath | 2000 |
A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Gl | 2000 |
A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Gl | 2000 |
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Drug Administratio | 2000 |
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Drug Administratio | 2000 |
Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch | 2001 |
Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch | 2001 |
A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a h
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch | 2001 |
A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a h
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch | 2001 |
Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2001 |
Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 2001 |
Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma.
Topics: Adolescent; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, P | 2001 |
Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma.
Topics: Adolescent; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, P | 2001 |
Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined C | 2002 |
Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined C | 2002 |
Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve | 2002 |
Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve | 2002 |
Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients.
Topics: Acetylcarnitine; Aged; Antineoplastic Agents; Carnitine; Cisplatin; Fatigue; Female; Humans; Ifosfam | 2002 |
Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients.
Topics: Acetylcarnitine; Aged; Antineoplastic Agents; Carnitine; Cisplatin; Fatigue; Female; Humans; Ifosfam | 2002 |
[Clinical experience with the cytostatic drug ifosfamide].
Topics: Adolescent; Adult; Aged; Bleomycin; Carcinoma; Clinical Trials as Topic; Cyclophosphamide; Drug Ther | 1977 |
[Clinical experience with the cytostatic drug ifosfamide].
Topics: Adolescent; Adult; Aged; Bleomycin; Carcinoma; Clinical Trials as Topic; Cyclophosphamide; Drug Ther | 1977 |
Advances in cancer management--an essay on the application of basic science principles.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Division; Clinical Trials as Topic; Cytological Tec | 1979 |
Advances in cancer management--an essay on the application of basic science principles.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Division; Clinical Trials as Topic; Cytological Tec | 1979 |
[Ifosfamide in the treatment of solid tumors and their metastases].
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Tolerance; Female; Humans; | 1976 |
[Ifosfamide in the treatment of solid tumors and their metastases].
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Tolerance; Female; Humans; | 1976 |
Phase I clinical trial of a 3-day divided dose schedule of ifosfamide (NSC 109724).
Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Hematuria; Humans; Ifosfamide; Kidney Tubul | 1976 |
Phase I clinical trial of a 3-day divided dose schedule of ifosfamide (NSC 109724).
Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Hematuria; Humans; Ifosfamide; Kidney Tubul | 1976 |
Results obtained with fractionated ifosfamide massive-dose treatment in generalized malignant tumours.
Topics: Adolescent; Adult; Aged; Child; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Ifosfami | 1976 |
Results obtained with fractionated ifosfamide massive-dose treatment in generalized malignant tumours.
Topics: Adolescent; Adult; Aged; Child; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Ifosfami | 1976 |
Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Breast Neoplasms; Child; Clinical Trials as Topic; Cyclopho | 1976 |
Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Breast Neoplasms; Child; Clinical Trials as Topic; Cyclopho | 1976 |
[Experience with fractionate massive-dose Ifosfamid therapy of generalized malignant tumors].
Topics: Adolescent; Adult; Aged; Child; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Ifosfami | 1975 |
[Experience with fractionate massive-dose Ifosfamid therapy of generalized malignant tumors].
Topics: Adolescent; Adult; Aged; Child; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Ifosfami | 1975 |
Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplati | 1992 |
Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplati | 1992 |
The influence of age on nephrotoxicity following chemotherapy in children.
Topics: Age Factors; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; C | 1992 |
The influence of age on nephrotoxicity following chemotherapy in children.
Topics: Age Factors; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; C | 1992 |
Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 1992 |
Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 1992 |
[Comparison of the antiemetic effectiveness of granisetron and alizapride plus dexamethasone in cytostatic therapy].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Dexamethasone; Drug Therapy, Combination; Et | 1991 |
[Comparison of the antiemetic effectiveness of granisetron and alizapride plus dexamethasone in cytostatic therapy].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Dexamethasone; Drug Therapy, Combination; Et | 1991 |
Metabolism and pharmacokinetics of oral and intravenous ifosfamide.
Topics: Acetaldehyde; Administration, Oral; Adult; Aged; Female; Humans; Ifosfamide; Infusions, Intravenous; | 1991 |
Metabolism and pharmacokinetics of oral and intravenous ifosfamide.
Topics: Acetaldehyde; Administration, Oral; Adult; Aged; Female; Humans; Ifosfamide; Infusions, Intravenous; | 1991 |
Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Com | 1991 |
Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Com | 1991 |
A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Com | 1991 |
A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Com | 1991 |
Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplati | 1991 |
Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplati | 1991 |
[The use of holoxan (iphosphamide) in malignant tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Infusio | 1990 |
[The use of holoxan (iphosphamide) in malignant tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Infusio | 1990 |
Ifosfamide--pharmacology, safety and therapeutic potential.
Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu | 1985 |
Ifosfamide--pharmacology, safety and therapeutic potential.
Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu | 1985 |
134 other studies available for ifosfamide and Neoplasms
| Article | Year |
|---|---|
Excellent Tolerability of Ifosfamide and Mesna Via Continuous Infusion in a Pediatric Patient Population.
Topics: Child; Drug Administration Schedule; Humans; Ifosfamide; Infusions, Intravenous; Mesna; Neoplasms | 2022 |
Excellent Tolerability of Ifosfamide and Mesna Via Continuous Infusion in a Pediatric Patient Population.
Topics: Child; Drug Administration Schedule; Humans; Ifosfamide; Infusions, Intravenous; Mesna; Neoplasms | 2022 |
Chemotherapy induced kidney and urinary tract related complications: A study in the Department of Pediatric Oncology and Hematology.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Female; Hematology; Humans; Ifosfamide; | 2022 |
Chemotherapy induced kidney and urinary tract related complications: A study in the Department of Pediatric Oncology and Hematology.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Female; Hematology; Humans; Ifosfamide; | 2022 |
Gastrointestinal bleeding/ulcer among paediatric cancer patients after proton beam therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Doxorubic | 2023 |
Gastrointestinal bleeding/ulcer among paediatric cancer patients after proton beam therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Doxorubic | 2023 |
Tolerability of ifosfamide-containing regimen in patients with high-risk renal and INI-1-deficient tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclophosphami | 2023 |
Tolerability of ifosfamide-containing regimen in patients with high-risk renal and INI-1-deficient tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclophosphami | 2023 |
Cellular senescence in kidney biopsies is associated with tubular dysfunction and predicts CKD progression in childhood cancer patients with karyomegalic interstitial nephropathy.
Topics: Biopsy; Cellular Senescence; Child; Humans; Ifosfamide; In Situ Hybridization, Fluorescence; Kidney; | 2023 |
Cellular senescence in kidney biopsies is associated with tubular dysfunction and predicts CKD progression in childhood cancer patients with karyomegalic interstitial nephropathy.
Topics: Biopsy; Cellular Senescence; Child; Humans; Ifosfamide; In Situ Hybridization, Fluorescence; Kidney; | 2023 |
Analysis of
Topics: Adolescent; Alleles; Child; Child, Preschool; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C9; Cyto | 2020 |
Analysis of
Topics: Adolescent; Alleles; Child; Child, Preschool; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C9; Cyto | 2020 |
Ifosfamide-related encephalopathy with severe clinical presentations in children with cancer.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Diseases; Child; Female; Humans; Ifosfamide; Me | 2021 |
Ifosfamide-related encephalopathy with severe clinical presentations in children with cancer.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Diseases; Child; Female; Humans; Ifosfamide; Me | 2021 |
Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study.
Topics: Acute Kidney Injury; Antineoplastic Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C | 2018 |
Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study.
Topics: Acute Kidney Injury; Antineoplastic Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C | 2018 |
Clinical and EEG Characteristics of Ifosfamide-Related Encephalopathy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Electroencephalography; | 2019 |
Clinical and EEG Characteristics of Ifosfamide-Related Encephalopathy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Electroencephalography; | 2019 |
Long-term nephrotoxicity in adult survivors of childhood cancer.
Topics: Adolescent; Adult; Albuminuria; Antineoplastic Agents; beta 2-Microglobulin; Biomarkers; Chemotherap | 2013 |
Long-term nephrotoxicity in adult survivors of childhood cancer.
Topics: Adolescent; Adult; Albuminuria; Antineoplastic Agents; beta 2-Microglobulin; Biomarkers; Chemotherap | 2013 |
N-acetylcysteine rescue protocol for nephrotoxicity in children caused by ifosfamide.
Topics: Acetylcysteine; Animals; Antidotes; Antineoplastic Agents, Alkylating; Antioxidants; Child; Drug Adm | 2013 |
N-acetylcysteine rescue protocol for nephrotoxicity in children caused by ifosfamide.
Topics: Acetylcysteine; Animals; Antidotes; Antineoplastic Agents, Alkylating; Antioxidants; Child; Drug Adm | 2013 |
PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics.
Topics: Antineoplastic Agents, Alkylating; Cytochrome P-450 Enzyme System; Humans; Ifosfamide; Neoplasms; Ph | 2014 |
PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics.
Topics: Antineoplastic Agents, Alkylating; Cytochrome P-450 Enzyme System; Humans; Ifosfamide; Neoplasms; Ph | 2014 |
Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents.
Topics: Adolescent; Antineoplastic Agents; Carnitine; Child; Child, Preschool; Cisplatin; Dose-Response Rela | 2015 |
Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents.
Topics: Adolescent; Antineoplastic Agents; Carnitine; Child; Child, Preschool; Cisplatin; Dose-Response Rela | 2015 |
Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Arachidonic Acids; Asbestos; Asbestosis; Attitude | 2014 |
Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Arachidonic Acids; Asbestos; Asbestosis; Attitude | 2014 |
Investigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models.
Topics: Acetaldehyde; Antineoplastic Agents, Alkylating; Bayes Theorem; Cells, Cultured; Hepatocytes; Ifosfa | 2016 |
Investigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models.
Topics: Acetaldehyde; Antineoplastic Agents, Alkylating; Bayes Theorem; Cells, Cultured; Hepatocytes; Ifosfa | 2016 |
Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: A retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Creatinine; Female; Humans; Ifosfami | 2016 |
Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: A retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Creatinine; Female; Humans; Ifosfami | 2016 |
A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors.
Topics: Adolescent; Adult; Child; Child, Preschool; Cystitis; Drug Administration Schedule; Female; Hemorrha | 2016 |
A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors.
Topics: Adolescent; Adult; Child; Child, Preschool; Cystitis; Drug Administration Schedule; Female; Hemorrha | 2016 |
Synthesis of novel monomeric graphene quantum dots and corresponding nanocomposite with molecularly imprinted polymer for electrochemical detection of an anticancerous ifosfamide drug.
Topics: Biosensing Techniques; Electrochemical Techniques; Graphite; Humans; Ifosfamide; Limit of Detection; | 2017 |
Synthesis of novel monomeric graphene quantum dots and corresponding nanocomposite with molecularly imprinted polymer for electrochemical detection of an anticancerous ifosfamide drug.
Topics: Biosensing Techniques; Electrochemical Techniques; Graphite; Humans; Ifosfamide; Limit of Detection; | 2017 |
Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; C | 2009 |
Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; C | 2009 |
Neurotoxicity during ifosfamide treatment in children.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Cyclophosphamide; Female; Hu | 2009 |
Neurotoxicity during ifosfamide treatment in children.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Cyclophosphamide; Female; Hu | 2009 |
Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cy | 2009 |
Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cy | 2009 |
Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Biomarkers; Child; Cyclophosphamide; Dose-Resp | 2009 |
Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Biomarkers; Child; Cyclophosphamide; Dose-Resp | 2009 |
Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin.
Topics: Adenosine Triphosphate; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot | 2009 |
Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin.
Topics: Adenosine Triphosphate; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot | 2009 |
Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Female | 2010 |
Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Female | 2010 |
Transcriptomic analysis of the effect of ifosfamide on MDCK cells cultivated in microfluidic biochips.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Culture Techniques; Dogs; Drug Evaluation, Preclini | 2012 |
Transcriptomic analysis of the effect of ifosfamide on MDCK cells cultivated in microfluidic biochips.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Culture Techniques; Dogs; Drug Evaluation, Preclini | 2012 |
Predictive value of circulating immature cell counts in peripheral blood for timing of peripheral blood progenitor cell collection after G-CSF plus chemotherapy-induced mobilization.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell | 2002 |
Predictive value of circulating immature cell counts in peripheral blood for timing of peripheral blood progenitor cell collection after G-CSF plus chemotherapy-induced mobilization.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell | 2002 |
Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Antineoplastic Agents, Alk | 2003 |
Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Antineoplastic Agents, Alk | 2003 |
[Polymorphism at the glutathione S-transferase pi locus as a risk factor for ifosfamide nephrotoxicity in children].
Topics: Adolescent; Child; Child, Preschool; Female; Gene Deletion; Genotype; Glomerular Filtration Rate; Gl | 2003 |
[Polymorphism at the glutathione S-transferase pi locus as a risk factor for ifosfamide nephrotoxicity in children].
Topics: Adolescent; Child; Child, Preschool; Female; Gene Deletion; Genotype; Glomerular Filtration Rate; Gl | 2003 |
Treatment of ifosfamide encephalopathy with intravenous thiamin.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Diseases; Humans; Ifosfamide; Infusions, Intravenous | 2003 |
Treatment of ifosfamide encephalopathy with intravenous thiamin.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Diseases; Humans; Ifosfamide; Infusions, Intravenous | 2003 |
Incidence and severity of ifosfamide-induced encephalopathy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cohort Studies; Dose-Response Relationship, Drug; Fe | 2004 |
Incidence and severity of ifosfamide-induced encephalopathy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cohort Studies; Dose-Response Relationship, Drug; Fe | 2004 |
Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Comet Assay; DNA Damage; Female; | 2005 |
Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Comet Assay; DNA Damage; Female; | 2005 |
Determination of thiamine and its phosphorylated forms in human plasma, erythrocytes and urine by HPLC and fluorescence detection: a preliminary study on cancer patients.
Topics: Chromatography, High Pressure Liquid; Erythrocytes; Humans; Ifosfamide; Neoplasms; Phosphorylation; | 2005 |
Determination of thiamine and its phosphorylated forms in human plasma, erythrocytes and urine by HPLC and fluorescence detection: a preliminary study on cancer patients.
Topics: Chromatography, High Pressure Liquid; Erythrocytes; Humans; Ifosfamide; Neoplasms; Phosphorylation; | 2005 |
Subsieve-size agarose capsules enclosing ifosfamide-activating cells: a strategy toward chemotherapeutic targeting to tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biophysics; Cats; Cell Line; Cell | 2005 |
Subsieve-size agarose capsules enclosing ifosfamide-activating cells: a strategy toward chemotherapeutic targeting to tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biophysics; Cats; Cell Line; Cell | 2005 |
[Ifosfamide induced encephalopathy: 15 observations].
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Coma; Enzyme Inhibitors; Fat | 2006 |
[Ifosfamide induced encephalopathy: 15 observations].
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Coma; Enzyme Inhibitors; Fat | 2006 |
Nonconvulsive status epilepticus due to ifosfamide.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Diazepam; Female; Humans; Ifosfamide; Levetirace | 2006 |
Nonconvulsive status epilepticus due to ifosfamide.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Diazepam; Female; Humans; Ifosfamide; Levetirace | 2006 |
Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Aryl Hydrocarbon Hydroxylases; Catalysis; | 2006 |
Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Aryl Hydrocarbon Hydroxylases; Catalysis; | 2006 |
[Perfect drug targeting. Glufosfamide a new derivative].
Topics: Antineoplastic Agents, Alkylating; Cyclophosphamide; DNA, Neoplasm; Drug Delivery Systems; Glucose; | 2006 |
[Perfect drug targeting. Glufosfamide a new derivative].
Topics: Antineoplastic Agents, Alkylating; Cyclophosphamide; DNA, Neoplasm; Drug Delivery Systems; Glucose; | 2006 |
Progress in the development of childhood cancer therapy.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Chromosomes; Cyclophosphamid | 2006 |
Progress in the development of childhood cancer therapy.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Chromosomes; Cyclophosphamid | 2006 |
[Psychotic states of mind in the course of ifosfamide therapy and prevention with piracetam (Nootrop). Preliminary report].
Topics: Adult; Aged; Cyclophosphamide; Humans; Ifosfamide; Middle Aged; Neoplasms; Piracetam; Psychoses, Sub | 1983 |
[Psychotic states of mind in the course of ifosfamide therapy and prevention with piracetam (Nootrop). Preliminary report].
Topics: Adult; Aged; Cyclophosphamide; Humans; Ifosfamide; Middle Aged; Neoplasms; Piracetam; Psychoses, Sub | 1983 |
Proceedings of a symposium on ifosfamide (Mitoxana; Holoxan) and Mesna (Uromitexan). Coventry, U.K., 16-18 March 1983.
Topics: Animals; Cyclophosphamide; Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms | 1983 |
Proceedings of a symposium on ifosfamide (Mitoxana; Holoxan) and Mesna (Uromitexan). Coventry, U.K., 16-18 March 1983.
Topics: Animals; Cyclophosphamide; Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms | 1983 |
Ifosfamide, mesna and vincristine in paediatric oncology.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Humans; Ifosfam | 1983 |
Ifosfamide, mesna and vincristine in paediatric oncology.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Humans; Ifosfam | 1983 |
High-dose ifosfamide and mesna as continuous infusion over five days--a phase I/II trial.
Topics: Cyclophosphamide; Drug Evaluation; Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms | 1983 |
High-dose ifosfamide and mesna as continuous infusion over five days--a phase I/II trial.
Topics: Cyclophosphamide; Drug Evaluation; Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms | 1983 |
Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.
Topics: Cyclophosphamide; Drug Evaluation; Drug Interactions; Female; Humans; Ifosfamide; Male; Mercaptoetha | 1983 |
Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.
Topics: Cyclophosphamide; Drug Evaluation; Drug Interactions; Female; Humans; Ifosfamide; Male; Mercaptoetha | 1983 |
Treatment of refractory malignant neoplasms with ifosfamide as single agent and in combination chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Ifosfamide; | 1983 |
Treatment of refractory malignant neoplasms with ifosfamide as single agent and in combination chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Ifosfamide; | 1983 |
Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.
Topics: Adult; Aged; Cyclophosphamide; Female; Humans; Ifosfamide; Kidney Diseases; Leukopenia; Male; Mercap | 1982 |
Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.
Topics: Adult; Aged; Cyclophosphamide; Female; Humans; Ifosfamide; Kidney Diseases; Leukopenia; Male; Mercap | 1982 |
Prophylaxis of ifosfamide toxicity with oral acetylcysteine.
Topics: Acetylcysteine; Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Dose-Response Rela | 1983 |
Prophylaxis of ifosfamide toxicity with oral acetylcysteine.
Topics: Acetylcysteine; Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Dose-Response Rela | 1983 |
High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Drug | 1980 |
High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Drug | 1980 |
Pronounced antiemetic activity of the antipsychotic drug levomepromacine (L) in patients receiving cancer chemotherapy.
Topics: Antineoplastic Agents; Cisplatin; Doxorubicin; Humans; Ifosfamide; Male; Methotrimeprazine; Neoplasm | 1980 |
Pronounced antiemetic activity of the antipsychotic drug levomepromacine (L) in patients receiving cancer chemotherapy.
Topics: Antineoplastic Agents; Cisplatin; Doxorubicin; Humans; Ifosfamide; Male; Methotrimeprazine; Neoplasm | 1980 |
[Ventricular premature contraction observed after anti-cancer chemotherapy with ifosfamide].
Topics: Aged; Cardiac Complexes, Premature; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasms | 1994 |
[Ventricular premature contraction observed after anti-cancer chemotherapy with ifosfamide].
Topics: Aged; Cardiac Complexes, Premature; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasms | 1994 |
Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bon | 1995 |
Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation.
Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bon | 1995 |
Ifosfamide: let's not end the honeymoon too soon.
Topics: Cyclophosphamide; Drug Resistance; Humans; Ifosfamide; Neoplasms | 1995 |
Ifosfamide: let's not end the honeymoon too soon.
Topics: Cyclophosphamide; Drug Resistance; Humans; Ifosfamide; Neoplasms | 1995 |
Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin.
Topics: Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Divisi | 1993 |
Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin.
Topics: Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Divisi | 1993 |
Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
Topics: Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Pla | 1993 |
Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
Topics: Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Pla | 1993 |
Ifosfamide treatment as a 10-day continuous intravenous infusion.
Topics: Adult; Aged; Bone Marrow; Humans; Ifosfamide; Infusions, Intravenous; Middle Aged; Neoplasms | 1995 |
Ifosfamide treatment as a 10-day continuous intravenous infusion.
Topics: Adult; Aged; Bone Marrow; Humans; Ifosfamide; Infusions, Intravenous; Middle Aged; Neoplasms | 1995 |
Technetium-99m dimercaptosuccinic acid and ifosfamide tubular dysfunction in children with cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dose-Response Relationship, | 1994 |
Technetium-99m dimercaptosuccinic acid and ifosfamide tubular dysfunction in children with cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dose-Response Relationship, | 1994 |
Estimation of ifosfamide/cisplatinum-induced renal toxicity by urinary protein analysis.
Topics: Adolescent; Adult; Child; Child, Preschool; Cisplatin; Drug Therapy, Combination; Electrophoresis, P | 1994 |
Estimation of ifosfamide/cisplatinum-induced renal toxicity by urinary protein analysis.
Topics: Adolescent; Adult; Child; Child, Preschool; Cisplatin; Drug Therapy, Combination; Electrophoresis, P | 1994 |
Ifosfamide enantiomers: pharmacokinetics in children.
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Female; Half-Life; Humans; Ifosfa | 1994 |
Ifosfamide enantiomers: pharmacokinetics in children.
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Female; Half-Life; Humans; Ifosfa | 1994 |
Hallucinations and ifosfamide-induced neurotoxicity.
Topics: Adult; Bone Marrow Transplantation; Female; Hallucinations; Humans; Ifosfamide; Male; Middle Aged; N | 1994 |
Hallucinations and ifosfamide-induced neurotoxicity.
Topics: Adult; Bone Marrow Transplantation; Female; Hallucinations; Humans; Ifosfamide; Male; Middle Aged; N | 1994 |
[The clinical effect of factor XIII on drug-induced hemorrhagic cystitis].
Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Cystitis; Factor XIII; Female; Hemorrhage; Hu | 1994 |
[The clinical effect of factor XIII on drug-induced hemorrhagic cystitis].
Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Cystitis; Factor XIII; Female; Hemorrhage; Hu | 1994 |
Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.
Topics: Adolescent; Adult; Child; Child, Preschool; Cisplatin; Fanconi Syndrome; Humans; Ifosfamide; Infant; | 1994 |
Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.
Topics: Adolescent; Adult; Child; Child, Preschool; Cisplatin; Fanconi Syndrome; Humans; Ifosfamide; Infant; | 1994 |
Renal function abnormalities after ifosfamide treatment in children.
Topics: Adolescent; Child; Child, Preschool; Cross-Sectional Studies; Female; Humans; Ifosfamide; Kidney Dis | 1993 |
Renal function abnormalities after ifosfamide treatment in children.
Topics: Adolescent; Child; Child, Preschool; Cross-Sectional Studies; Female; Humans; Ifosfamide; Kidney Dis | 1993 |
Ifosfamide neurotoxicity. A challenge for nurses, a potential nightmare for patients.
Topics: Brain Diseases; Carcinoma, Small Cell; Central Nervous System; Female; Humans; Ifosfamide; Lung Neop | 1993 |
Ifosfamide neurotoxicity. A challenge for nurses, a potential nightmare for patients.
Topics: Brain Diseases; Carcinoma, Small Cell; Central Nervous System; Female; Humans; Ifosfamide; Lung Neop | 1993 |
Partial and complete de Toni-Debré-Fanconi syndrome after ifosfamide chemotherapy of childhood malignancy.
Topics: Child; Cisplatin; Fanconi Syndrome; Humans; Ifosfamide; Kidney Function Tests; Kidney Glomerulus; Ki | 1993 |
Partial and complete de Toni-Debré-Fanconi syndrome after ifosfamide chemotherapy of childhood malignancy.
Topics: Child; Cisplatin; Fanconi Syndrome; Humans; Ifosfamide; Kidney Function Tests; Kidney Glomerulus; Ki | 1993 |
Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Etoposide; Humans; Ifosfamide; Neo | 1995 |
Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Etoposide; Humans; Ifosfamide; Neo | 1995 |
Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agen | 1996 |
Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agen | 1996 |
Ifosfamide and paediatrics: should this marriage be saved?
Topics: Antineoplastic Agents, Alkylating; Child; Humans; Ifosfamide; Kidney; Neoplasms; Rhabdomyosarcoma | 1996 |
Ifosfamide and paediatrics: should this marriage be saved?
Topics: Antineoplastic Agents, Alkylating; Child; Humans; Ifosfamide; Kidney; Neoplasms; Rhabdomyosarcoma | 1996 |
[Ifosfamide in pediatric malignancy--experiences in the Northern Israel Oncology Center].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C | 1996 |
[Ifosfamide in pediatric malignancy--experiences in the Northern Israel Oncology Center].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C | 1996 |
Risk factors for ifosfamide nephrotoxicity in children.
Topics: Adolescent; Child; Child, Preschool; Cohort Studies; Female; Glomerular Filtration Rate; Humans; Ifo | 1996 |
Risk factors for ifosfamide nephrotoxicity in children.
Topics: Adolescent; Child; Child, Preschool; Cohort Studies; Female; Glomerular Filtration Rate; Humans; Ifo | 1996 |
The influence of ifosfamide scheduling on acute nephrotoxicity in children.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Creatinine; Drug Administrat | 1997 |
The influence of ifosfamide scheduling on acute nephrotoxicity in children.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Creatinine; Drug Administrat | 1997 |
6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Female; Granulocyte Colony-Stimulating Factor; | 1997 |
6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Female; Granulocyte Colony-Stimulating Factor; | 1997 |
Nephrotoxicity of high-dose ifosfamide/carboplatin/etoposide in adults undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bicarbonates; Carboplatin; Creati | 1997 |
Nephrotoxicity of high-dose ifosfamide/carboplatin/etoposide in adults undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bicarbonates; Carboplatin; Creati | 1997 |
[Biochemical parameters in the diagnosis of nephrotoxicity of antineoplastic chemotherapy in children].
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Cispl | 1997 |
[Biochemical parameters in the diagnosis of nephrotoxicity of antineoplastic chemotherapy in children].
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Cispl | 1997 |
Acute changes in urine protein excretion may predict chronic ifosfamide nephrotoxicity: a preliminary observation.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Chronic Disease; Female; Hum | 1998 |
Acute changes in urine protein excretion may predict chronic ifosfamide nephrotoxicity: a preliminary observation.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Chronic Disease; Female; Hum | 1998 |
Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
Topics: Acetaldehyde; Acrolein; Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Female; Humans; | 1998 |
Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
Topics: Acetaldehyde; Acrolein; Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Female; Humans; | 1998 |
Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children.
Topics: Adolescent; Antineoplastic Agents; Biotransformation; Brain Neoplasms; Child; Child, Preschool; Cycl | 1997 |
Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children.
Topics: Adolescent; Antineoplastic Agents; Biotransformation; Brain Neoplasms; Child; Child, Preschool; Cycl | 1997 |
Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
Topics: Adult; Amino Acids; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocol | 1997 |
Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
Topics: Adult; Amino Acids; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocol | 1997 |
Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cells; Bromisovalum; Drug Administration Sched | 1995 |
Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cells; Bromisovalum; Drug Administration Sched | 1995 |
Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Fanconi Syndrome; Fol | 1999 |
Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Fanconi Syndrome; Fol | 1999 |
Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colony-Forming Units Assay; Cyclophosphamide; Drug S | 1999 |
Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colony-Forming Units Assay; Cyclophosphamide; Drug S | 1999 |
Possible metabolic interaction between docetaxel and ifosfamide.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-R | 2000 |
Possible metabolic interaction between docetaxel and ifosfamide.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-R | 2000 |
Initial measurements of ifosfamide and cyclophosphamide in patients using (31)P MRS: pulse-and-acquire, decoupling, and polarization transfer.
Topics: Antineoplastic Agents, Alkylating; Cyclophosphamide; Humans; Ifosfamide; Liver; Magnetic Resonance S | 2000 |
Initial measurements of ifosfamide and cyclophosphamide in patients using (31)P MRS: pulse-and-acquire, decoupling, and polarization transfer.
Topics: Antineoplastic Agents, Alkylating; Cyclophosphamide; Humans; Ifosfamide; Liver; Magnetic Resonance S | 2000 |
New insights into the pharmacokinetics and metabolism of (R,S)-ifosfamide in cancer patients using a population pharmacokinetic-metabolism model.
Topics: Antineoplastic Agents, Alkylating; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2B6; Cytochrom | 2000 |
New insights into the pharmacokinetics and metabolism of (R,S)-ifosfamide in cancer patients using a population pharmacokinetic-metabolism model.
Topics: Antineoplastic Agents, Alkylating; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2B6; Cytochrom | 2000 |
Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials.
Topics: Antineoplastic Agents, Alkylating; Biometry; Clinical Trials as Topic; Humans; Ifosfamide; Leukemia, | 1999 |
Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials.
Topics: Antineoplastic Agents, Alkylating; Biometry; Clinical Trials as Topic; Humans; Ifosfamide; Leukemia, | 1999 |
Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Child; Child, Preschool; Fea | 2001 |
Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Child; Child, Preschool; Fea | 2001 |
Ifosfamide nephrotoxicity in pediatric cancer patients.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Cisplatin; Female; Humans; I | 2001 |
Ifosfamide nephrotoxicity in pediatric cancer patients.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Cisplatin; Female; Humans; I | 2001 |
The utility of (99m)Tc-DMSA and Tc(99m)-EC scintigraphy for early diagnosis of ifosfamide induced nephrotoxicity.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; beta | 2001 |
The utility of (99m)Tc-DMSA and Tc(99m)-EC scintigraphy for early diagnosis of ifosfamide induced nephrotoxicity.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; beta | 2001 |
[Prophylactic alkalization of the urine during cytostatic tumor treatment with the oxazaphosphorine derivatives, cyclophosphamide and ifosfamide].
Topics: Alkalies; Cyclophosphamide; Cystitis; Female; Hemorrhage; Humans; Hydrogen-Ion Concentration; Ifosfa | 1979 |
[Prophylactic alkalization of the urine during cytostatic tumor treatment with the oxazaphosphorine derivatives, cyclophosphamide and ifosfamide].
Topics: Alkalies; Cyclophosphamide; Cystitis; Female; Hemorrhage; Humans; Hydrogen-Ion Concentration; Ifosfa | 1979 |
Report on carcinogenesis bioassay of isophosphamide.
Topics: Animals; Carcinogens; Cyclophosphamide; Cystitis; Dogs; Female; Hair; Ifosfamide; Lymphoma; Male; Ma | 1978 |
Report on carcinogenesis bioassay of isophosphamide.
Topics: Animals; Carcinogens; Cyclophosphamide; Cystitis; Dogs; Female; Hair; Ifosfamide; Lymphoma; Male; Ma | 1978 |
[Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)].
Topics: Adult; Aged; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Hodgkin Disease; | 1978 |
[Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)].
Topics: Adult; Aged; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Hodgkin Disease; | 1978 |
Mass spectrometric characterization of activated N-(2-chloroethyl)amino oxazaphosphorine derivative.
Topics: Chemical Phenomena; Chemistry; Cyclophosphamide; Humans; Ifosfamide; Mass Spectrometry; Neoplasms | 1977 |
Mass spectrometric characterization of activated N-(2-chloroethyl)amino oxazaphosphorine derivative.
Topics: Chemical Phenomena; Chemistry; Cyclophosphamide; Humans; Ifosfamide; Mass Spectrometry; Neoplasms | 1977 |
[Clinical evaluation of Iphosphamide in phracological treatment of neoplasms].
Topics: Adult; Aged; Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Male; Middle Aged; Neopl | 1975 |
[Clinical evaluation of Iphosphamide in phracological treatment of neoplasms].
Topics: Adult; Aged; Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Male; Middle Aged; Neopl | 1975 |
[Phase II therapeutic trial (screening) of ifosfamide in hematosarcomas and solid tumors].
Topics: Cyclophosphamide; Drug Evaluation; Hemangiosarcoma; Humans; Ifosfamide; Neoplasms | 1975 |
[Phase II therapeutic trial (screening) of ifosfamide in hematosarcomas and solid tumors].
Topics: Cyclophosphamide; Drug Evaluation; Hemangiosarcoma; Humans; Ifosfamide; Neoplasms | 1975 |
Pharmacokinetics of divided-dose ifosfamide.
Topics: Alkylating Agents; Computers; Cyclophosphamide; Drug Administration Schedule; Humans; Ifosfamide; Ki | 1976 |
Pharmacokinetics of divided-dose ifosfamide.
Topics: Alkylating Agents; Computers; Cyclophosphamide; Drug Administration Schedule; Humans; Ifosfamide; Ki | 1976 |
Reduction of ifosfamide toxicity using dose fractionation.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Administration Schedule; Female; Hematuria; Humans; | 1976 |
Reduction of ifosfamide toxicity using dose fractionation.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Administration Schedule; Female; Hematuria; Humans; | 1976 |
Current developments and future directions with ifosfamide: an update. Proceedings of a satellite symposium of the XV Congress of the European Society for Medical Oncology. Copenhagen, Denmark, December 2, 1990.
Topics: Animals; Humans; Ifosfamide; Neoplasms | 1992 |
Current developments and future directions with ifosfamide: an update. Proceedings of a satellite symposium of the XV Congress of the European Society for Medical Oncology. Copenhagen, Denmark, December 2, 1990.
Topics: Animals; Humans; Ifosfamide; Neoplasms | 1992 |
Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin.
Topics: Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cell Coun | 1992 |
Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin.
Topics: Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cell Coun | 1992 |
Uroepithelial and nephrotubular toxicity in patients receiving ifosfamide/mesna: measurement of urinary N-acetyl-beta-D-glucosaminidase and beta-2-microglobulin.
Topics: Acetylglucosaminidase; Adult; Aged; beta 2-Microglobulin; Creatinine; Female; Humans; Ifosfamide; Ki | 1992 |
Uroepithelial and nephrotubular toxicity in patients receiving ifosfamide/mesna: measurement of urinary N-acetyl-beta-D-glucosaminidase and beta-2-microglobulin.
Topics: Acetylglucosaminidase; Adult; Aged; beta 2-Microglobulin; Creatinine; Female; Humans; Ifosfamide; Ki | 1992 |
Encephalopathy in ifosfamide-treated patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Diseases; Female; Humans; Ifosfam | 1992 |
Encephalopathy in ifosfamide-treated patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Diseases; Female; Humans; Ifosfam | 1992 |
Dose escalation of cisplatin (P), etoposide (E), and ifosfamide (I) with GM-CSF for advanced germ cell tumors.
Topics: Cisplatin; Drug Therapy, Combination; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; H | 1992 |
Dose escalation of cisplatin (P), etoposide (E), and ifosfamide (I) with GM-CSF for advanced germ cell tumors.
Topics: Cisplatin; Drug Therapy, Combination; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; H | 1992 |
Iphosphamide-induced nephrotoxicity in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Humans; Ifosfamide; Infant; | 1992 |
Iphosphamide-induced nephrotoxicity in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Humans; Ifosfamide; Infant; | 1992 |
Ifosfamide vs cyclophosphamide in cancer therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cyclophosphamide; Female; Genital Neoplasms, | 1991 |
Ifosfamide vs cyclophosphamide in cancer therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cyclophosphamide; Female; Genital Neoplasms, | 1991 |
Ifosfamide in Tumor Therapy: Questions for the Nineties. Satellite Symposium, 15th International Cancer Congress, Hamburg, 1990.
Topics: Humans; Ifosfamide; Neoplasms | 1991 |
Ifosfamide in Tumor Therapy: Questions for the Nineties. Satellite Symposium, 15th International Cancer Congress, Hamburg, 1990.
Topics: Humans; Ifosfamide; Neoplasms | 1991 |
Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Admi | 1991 |
Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Admi | 1991 |
Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Biological Availabilit | 1991 |
Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Biological Availabilit | 1991 |
Determination of urinary 2- and 3-dechloroethylated metabolites of ifosfamide by high-performance liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Humans; Ifosfamide; Neoplasms; Oxidation-Reduction; Reproducib | 1991 |
Determination of urinary 2- and 3-dechloroethylated metabolites of ifosfamide by high-performance liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Humans; Ifosfamide; Neoplasms; Oxidation-Reduction; Reproducib | 1991 |
Ifosfamide for children with solid tumours.
Topics: Child; Child, Preschool; Glomerular Filtration Rate; Humans; Ifosfamide; Neoplasms; Nephritis, Inter | 1990 |
Ifosfamide for children with solid tumours.
Topics: Child; Child, Preschool; Glomerular Filtration Rate; Humans; Ifosfamide; Neoplasms; Nephritis, Inter | 1990 |
The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients.
Topics: Adult; Aged; Alkylation; Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Middle Aged; Neop | 1991 |
The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients.
Topics: Adult; Aged; Alkylation; Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Middle Aged; Neop | 1991 |
High-dose ifosfamide with mesna uroprotection: a phase I study.
Topics: Blood; Bone Marrow; Central Nervous System; Dose-Response Relationship, Drug; Drug Evaluation; Drug | 1990 |
High-dose ifosfamide with mesna uroprotection: a phase I study.
Topics: Blood; Bone Marrow; Central Nervous System; Dose-Response Relationship, Drug; Drug Evaluation; Drug | 1990 |
Basic principles in preclinical cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Evaluation, | 1990 |
Basic principles in preclinical cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Evaluation, | 1990 |
Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism.
Topics: Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Metabolic Clearance Rate; Neoplasms; Time | 1990 |
Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism.
Topics: Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Metabolic Clearance Rate; Neoplasms; Time | 1990 |
Advances in ifosfamide chemotherapy. Proceedings of a symposium. November 4-5, 1989, Key Biscayne, FL.
Topics: Humans; Ifosfamide; Neoplasms | 1990 |
Advances in ifosfamide chemotherapy. Proceedings of a symposium. November 4-5, 1989, Key Biscayne, FL.
Topics: Humans; Ifosfamide; Neoplasms | 1990 |
Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors.
Topics: Adolescent; Adult; Child; Cisplatin; Humans; Ifosfamide; Neoplasms; Nervous System Diseases; Risk | 1990 |
Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors.
Topics: Adolescent; Adult; Child; Cisplatin; Humans; Ifosfamide; Neoplasms; Nervous System Diseases; Risk | 1990 |
Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988.
Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Humans; Ifosfamide; Infant; Mercaptoethanol; M | 1989 |
Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988.
Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Humans; Ifosfamide; Infant; Mercaptoethanol; M | 1989 |
Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children.
Topics: Adolescent; Alkylation; Child; Child, Preschool; Colorimetry; Drug Evaluation; Drug Therapy, Combina | 1989 |
Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children.
Topics: Adolescent; Alkylation; Child; Child, Preschool; Colorimetry; Drug Evaluation; Drug Therapy, Combina | 1989 |
Ifosfamide in pediatric malignant solid tumors.
Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Drug Therapy, Combination; Humans; Ifosfamide; | 1989 |
Ifosfamide in pediatric malignant solid tumors.
Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Drug Therapy, Combination; Humans; Ifosfamide; | 1989 |
Toxicity of high-dose ifosfamide in children.
Topics: Adolescent; Bone Marrow; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Ifosfam | 1989 |
Toxicity of high-dose ifosfamide in children.
Topics: Adolescent; Bone Marrow; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Ifosfam | 1989 |
Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Mi | 1989 |
Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Mi | 1989 |
Mesna excretion and ifosfamide nephrotoxicity in children.
Topics: Adolescent; Adult; Child; Child, Preschool; Creatinine; Female; Humans; Ifosfamide; Kidney Diseases; | 1989 |
Mesna excretion and ifosfamide nephrotoxicity in children.
Topics: Adolescent; Adult; Child; Child, Preschool; Creatinine; Female; Humans; Ifosfamide; Kidney Diseases; | 1989 |
Current developments and future direction with ifosfamide. Proceedings of a satellite symposium of the European Society of Medical Oncology. October 31, 1988, Lugano, Switzerland.
Topics: Animals; Humans; Ifosfamide; Neoplasms | 1989 |
Current developments and future direction with ifosfamide. Proceedings of a satellite symposium of the European Society of Medical Oncology. October 31, 1988, Lugano, Switzerland.
Topics: Animals; Humans; Ifosfamide; Neoplasms | 1989 |
Ifosfamide in the treatment of pediatric malignancies. 4th European Conference on Clinical Oncology and Cancer Nursing. Madrid, November 1987. Proceedings.
Topics: Child; Humans; Ifosfamide; Neoplasms | 1989 |
Ifosfamide in the treatment of pediatric malignancies. 4th European Conference on Clinical Oncology and Cancer Nursing. Madrid, November 1987. Proceedings.
Topics: Child; Humans; Ifosfamide; Neoplasms | 1989 |
A phase II study of ifosfamide in paediatric solid tumours.
Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Drug Tolerance; Female; Humans; Ifosfamide; In | 1989 |
A phase II study of ifosfamide in paediatric solid tumours.
Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Drug Tolerance; Female; Humans; Ifosfamide; In | 1989 |
Experience with ifosfamide in paediatric tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Drug Evaluation; Humans; Ifosfamide; Neoplasm | 1989 |
Experience with ifosfamide in paediatric tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Drug Evaluation; Humans; Ifosfamide; Neoplasm | 1989 |
Ifosfamide cardiotoxicity in humans.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Female; Humans; I | 1989 |
Ifosfamide cardiotoxicity in humans.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Female; Humans; I | 1989 |
Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; | 1986 |
Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; | 1986 |
Phase II trial of ifosfamide in children with malignant solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drug Eva | 1987 |
Phase II trial of ifosfamide in children with malignant solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drug Eva | 1987 |
Recent experience with ifosfamide/mesna in solid tumors. International satellite symposium to the 3rd European Conference on Clinical Oncology. Stockholm, June 1985. Proceedings.
Topics: Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms | 1986 |
Recent experience with ifosfamide/mesna in solid tumors. International satellite symposium to the 3rd European Conference on Clinical Oncology. Stockholm, June 1985. Proceedings.
Topics: Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms | 1986 |
The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
Topics: Adolescent; Adult; Child; Child, Preschool; Cyclophosphamide; Cystitis; Female; Hematuria; Hemorrhag | 1987 |
The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
Topics: Adolescent; Adult; Child; Child, Preschool; Cyclophosphamide; Cystitis; Female; Hematuria; Hemorrhag | 1987 |
Treatment of advanced malignancies with ifosfamide under protection with mesna.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Male; Mesna | 1988 |
Treatment of advanced malignancies with ifosfamide under protection with mesna.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Male; Mesna | 1988 |
Ifosfamide and Mesna in advanced malignancies.
Topics: Adult; Aged; Carcinoma, Bronchogenic; Female; Hematuria; Humans; Ifosfamide; Lung Neoplasms; Lymphom | 1988 |
Ifosfamide and Mesna in advanced malignancies.
Topics: Adult; Aged; Carcinoma, Bronchogenic; Female; Hematuria; Humans; Ifosfamide; Lung Neoplasms; Lymphom | 1988 |
Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.
Topics: Adult; Aged; Alkylation; Debrisoquin; Female; Humans; Ifosfamide; Isoquinolines; Male; Middle Aged; | 1988 |
Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.
Topics: Adult; Aged; Alkylation; Debrisoquin; Female; Humans; Ifosfamide; Isoquinolines; Male; Middle Aged; | 1988 |
Ifosfamide: an old drug recently rediscovered.
Topics: Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Male; Neoplasms; Sarcoma; Soft Tissue | 1988 |
Ifosfamide: an old drug recently rediscovered.
Topics: Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Male; Neoplasms; Sarcoma; Soft Tissue | 1988 |
[Ifosfamide treatment for children with malignant tumor].
Topics: Adolescent; Adult; Animals; Child; Child, Preschool; Female; Humans; Ifosfamide; Male; Mice; Mice, N | 1987 |
[Ifosfamide treatment for children with malignant tumor].
Topics: Adolescent; Adult; Animals; Child; Child, Preschool; Female; Humans; Ifosfamide; Male; Mice; Mice, N | 1987 |
Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.
Topics: Acetylglucosaminidase; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood; Chi | 1987 |
Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.
Topics: Acetylglucosaminidase; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood; Chi | 1987 |
A phase II study of ifosfamide in children with recurrent solid tumours.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drug Evaluation | 1985 |
A phase II study of ifosfamide in children with recurrent solid tumours.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drug Evaluation | 1985 |